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ABSTRACT 
Bovine viral diarrhea virus (BVDV) is a pestivirus that suppresses the innate and adaptive host 
immune responses.  Each of the two classified genotypes (BVDV1 and BVDV2) has two 
distinct biotypes – cytopathic (cp) and non-cytopathic (ncp) – and evidence has suggested that 
cytopathic strains may disrupt host interferon (IFN) synthesis and IFN-mediated responses.  
However, inconsistent results examining ncpBVDV strains have generated controversy 
regarding whether they also exhibit this capability.  The purpose for this study was to determine 
the occurrence and functionality of IFN-induced responses within the serum cattle infected with 
ncpBVDV2-1373.  Specifically, this involved analysing the changes in both the serum levels of 
IFN-α and IFN-γ and the expression of genes that are classically regulated by these cytokines.  
Serum analysis showed that the infected cattle induced both serum IFN-α and IFN-γ during 
BVDV infection while PBMC analysis showed increased expression of genes that classically 
respond to IFN-α – Mx-1, OAS-1, and STAT-1 – and IFN-γ – SOCS-1 and SOCS-3.  These 
findings are supported by temporal kinome analysis, which verified activation of the JAK-
STAT signalling network within the PBMCs of the virus-infected animals.  In addition to 
establishing evidence for its synthesis, results from this challenge identified IFN-γ as a possible 
indicator of animal mortality as analysis of its change within the non-surviving, infected 
animals was statistically greater than the levels of the surviving, infected animals.  Collectively, 
these results demonstrate 1373-mediated induction of, and host cell response to, both IFN-α and 
IFN–γ, and the potential for IFN-γ to be a predictive marker for mortality during BVDV 
infection.     
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1. INTRODUCTION 
 
1.1 OVERVIEW OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) 
 
1.1.1 Taxonomy 
Bovine Viral Diarrhea Virus (BVDV) is one of the most economically devastating pathogens in 
the global cattle industry. This is due to its role as a main contributor to loss and poor 
reproductive performance of cattle (Smirnova et al., 2008).  BVDV is a pestivirus within the 
Flaviviridae family, which, based on common structural and genetic traits, is grouped among 
several well-known viruses including West Nile Virus, hepatitis C virus (HCV), dengue virus, 
and yellow fever virus.  The common structural and genetic traits between these viruses include 
i) their non-polyadenylated, positive-sense, single-stranded RNA (+ssRNA) genome that 
translates into a single, precursor polyprotein; ii) the need to cleave this protein into multiple, 
mature structural and non-structural proteins using viral and cellular proteases; and iii) 
encompassing itself in an outer, glycoprotein-rich, lipid membrane obtained via budding 
through host cell, organelle membranes during the maturation step of its lifecycle (Neill, 2013).   
 Pestiviruses are currently organized into the following categories: classical swine fever 
virus (CSFV), border disease virus (BDV), and BVDV.  BVDV is further separated into two 
genotypically-based groups – BVDV1 and BVDV2 – which are distinguished by the 
differences in their E2 and Npro proteins, as well as their 5’ untranslated genomic regions.  
Strains within BVDV2 are more virulent and tend to initiate acute infections more often than 
BVDV1 strains.  Strains within these two genotypes can be phenotypically categorized into two 
biotypes on the basis of their lytic ability on epithelial tissue cultures in vitro: cytopathic (lytic) 
strains and non-cytopathic (non-lytic) strains (Smirnova et al., 2008; Gil et al., 2006).  Research 
has further lead to the putative inclusion of several other pestiviruses, including one that 
initiates a clinically similar response to the other two BVDV genotypes: “Hobi-like” virus or 
BVDV3 (Pellerin et al., 1994; Bauermann et al., 2014, Bauermann et al., 2013).     
 The non-cytopathic and cytopathic biotypes are antigenically similar and have a nearly 
indistinguishable genomic sequence.  Due to this similarity, cytopathic strains are thought to 
develop from pre-existing non-cytopathic strains via a variety of mutations that affect the 
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processing of the NS2/3 protein (Agapov et al., 2004).  Additionally, recent evidence from a 
thorough examination of its genome has suggested that the strains of BVDV3 are 
distinguishable by differences within a specific 3’-domain sequence of the non-structural 
protein, NS2 (Decaro et al., 2012).  
     
1.1.2 Physical Description of BVDV 
The structure of BVDV is comprised of the core region, which includes the viral genome; the 
capsid, which encompasses this genome; and the outer envelope consisting of a glycoprotein-
rich lipid bilayer, which is obtained by the virus during the assembly and maturation processes 
of its lifecycle.  This envelope makes BVDV susceptible to viral inactivation by heat, organic 
solvents, and detergents (Rumenapf et al., 1991).  Despite its pleiomorphic structure, BVDV 
has an estimated diameter between 40 and 60 nm.   
 
1.1.2.1 BVDV Genome 
BVDV houses a 12.3-kb, +ssRNA genome that is subject to high rates of mutation, which, in 
addition to the high recombination rate of genotypically-different strains, is due to the poor 
proofreading ability of the viral replicase enzyme (Brackenbury et al., 2003; Smirnova et al., 
2008).  High mutation rates are evolutionarily-beneficial for BVDV as this leads to 
heterogeneity, a characteristic that is essential for adaptation and evasion of host immune 
responses (Ridpath et al., 2003).  Structurally, the genome has a large open reading frame 
(ORF) that encodes all of its structural and non-structural proteins. Additionally, its 3’ and 5’ 
termini do not encode proteins, and are aptly classified as untranslated regions (UTRs) (Brock 
et al., 1992).  These UTRs tend to form secondary structures that are involved in a three-way 
interaction with certain viral and cellular proteins, which collectively regulate the replication 
and transcription of the genome, as well as the translation of the ORF (Yu et al., 2000). 
 Translation is often promoted by the interaction of the 5’ mRNA cap with the ribosome 
at the rough endoplasmic reticulum.  However, the BVDV genome does not have a cap; 
therefore, its translation begins at an internal ribosome entry site (IRES) located within the 5’ 
UTR.  This IRES is characterised as a tertiary structure that forms a series of smaller distinct 
shapes known as pseudoknots that are identified as A, B, C, D1, D2, D3, D4, and D5, all of 
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which are recognized by cellular translational proteins.  These proteins lead the ribosome to the 
viral +ssRNA so that it can bind and initiate translation at the correct AUG in a cap-
independent fashion.  Translation ultimately synthesizes a single, precursor polyprotein, which 
is further cleaved into twelve smaller (structural and non-structural) proteins by several cellular 
and viral proteases (Deng and Brock, 1992; Isken et al., 2004, Moes and Wirth, 2007).  
 
1.1.2.2 BVDV Proteins and their Functions 
The ORF of the BVDV ssRNA encodes four structural and eight non-structural proteins.  The 
structural proteins include the core protein (Cap) and three envelope glycoproteins – Erns, E1, 
and E2.  The non-structural proteins include p7, NS2, NS3, NS4a, NS4b, NS5a, NS5b, and 
Npro.  As mentioned, the regions encoding NS2 and NS3 may be translated separately or as a 
single protein (Neill, 2013).  Figure 1.1 shows the order in which these proteins are encoded on 
the BVDV genome from the 5’ end to the 3’ end. 
 
Figure 1.1: Structure and organization of BVDV genome.  A. Physical structure illustrating the 
precursor polyprotein is translated from the BVDV genome.  B. The order in which BVDV 
proteins are translated from the genome, including the uncleaved NS2-3 that is seen in 
ncpBVDV strains.  C. The separation of NS2 and NS3 as seen in cpBVDV strains. 
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 The structural proteins are incorporated into the virion and collectively comprise the 
capsid and the envelope.  Cap is the main core protein that comprises the protective structure 
encompassing the genome.  Erns is a loosely-attached, glycosylated protein that is expressed as a 
homodimer.  While it is a component of the viral envelope, Erns can also be secreted as a soluble 
protein that likely functions in countering host immune response, a role that will be discussed in 
more detail later (Schneider et al., 1993).  E1 and E2 are integral membrane glycoproteins.  
Little is known about E1, but recent evidence has shown that its heterodimerisation with E2 
plays a crucial role in virion entry (Ronecker et al., 2008).  Additionally, E2 is one of the main 
proteins which host antibodies (soluble, antigen-binding proteins) target.  Evidence has shown 
that antibodies can efficiently halt infection by just targeting E2 (Deregt et al., 1998).   
 The non-structural proteins encompass a variety of roles that are related to BVDV’s 
infectivity.  Npro is a self-protease that separates itself from the polyprotein immediately after 
translation and has been shown to block IRF3, a major role in interferon (IFN) suppression that 
will be detailed later (Chen et al., 2007).  p7 is thought to form an ion channel; thereby, 
facilitate viral movement between cells, which is similar to its role in HCV.  However, this 
suggestion is mainly based on the p7 function of HCV.  Little evidence has been gathered to 
confirm that its function is similar in BVDV (Griffin et al., 2004; Harada et al., 2000; Neill, 
2013).  As mentioned, NS2 and NS3 are the major determinants in BVDV biotype formation.  
They are mainly unprocessed – remain fused as NS2/3 – in non-cytopathic BVDV strains, 
while normally being distinct in cytopathic strains.  However, recent evidence suggests that 
NS2/3 cleavage is also required for early, non-cytopathic, viral replication; this fission rapidly 
dropping once sufficient viral replication has occurred (Lackner et al., 2004).  NS4a is involved 
in helping to cleave NS3 while NS4b functions in reconfiguring the membranes of infected 
cells and associating with the RNA replication complex (Xu et al., 1997; Weiskircher et al., 
2009).  The function of NS5a is largely unknown, but its accumulation is thought to inhibit 
IRES-dependent translation (Ridpath, 2005a).  Finally, NS5b is the virus’s RNA-dependent 
RNA polymerase, which catalyzes replication of the viral genome (Gong et al., 1996). 
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1.1.3 BVDV Lifecycle 
BVDV follows a stepwise lifecycle that is similar to most viruses: i) receptor-binding, ii) entry, 
iii) uncoating, iv) transcription, v) translation, vi) replication, vii) assembly, and viii) 
maturation and release.   
 
1.1.3.1 Entry to Translation 
As mentioned, E1-E2 heterodimerisation is critical for virion entry. This heterodimer initiates 
entry by binding to CD46, a receptor that promotes pH-dependent fusion of the viral envelope 
with the host cell membrane. This ultimately enables the virus to cross the host cell membrane 
via clathrin-dependent, receptor-mediated endocytosis.  BVDV is immediately brought into the 
lysosome, where it uncoats and releases its genetic material into the cell to be translated 
(Grummer et al., 2004; Maurer et al., 2004; Krey et al., 2006; Ronecker et al., 2008; Xue et al., 
1997; Zurcher et al., 2014).   
 
1.1.3.2 Replication 
Like other +ssRNA viruses, BVDV often replicates following an initial round of transcription 
and translation.  Its genome serves as the template on which replication is initiated.  A 
secondary structural motif located within the 5’ UTR serves to transfer the function from 
transcription to replication (Yu et al., 2000).  As mentioned, the increase in NS5A and NS5B 
proteins additionally serves to prevent further translation.  A viral replicase complex is 
assembled to mediate replication and requires the use of multiple, non-structural proteins 
(Ridpath, 2005).  Following translation, these proteins form into this replicase structure at the 3’ 
genome terminus in order to catalyze the transcription of the genome into a –ssRNA structure, 
which is used as the template off of which to replicate the BVDV genome, catalyzed via RNA-
dependent RNA polymerase; occurring within a membrane structure (Gong et al., 1998).     
 
1.1.3.3 Assembly and Maturation 
Following replication, assembly and maturation take place within intracellular vesicles at either 
the endoplasmic reticulum or the Golgi apparatus.  The lipid-based envelope is gathered via 
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vesicle budding at one of these organelles.  Ultimately, virions are released via exocytosis, 
nearly eight hours post-infection (Grummer et al., 2001; Nuttall, 1980).  
 As protein synthesis precedes replication, BVDV stimulates expression of host genes 
that function in translation and post-translational modification as a mechanism that favours its 
replication and continued presence in the host.  Additionally, it reduces expression of host 
genes involved in cell structure and energy production; therefore, prevents the host from 
responding to the virus before it can amplify its genome (Neill and Ridpath, 2003).  BVDV can 
be identified within infected cell cultures between 4 and 6 hours post-infection, with peak titres 
between 12 and 24 hours post-infection (Gong et al., 1996).  
 
1.1.4 Mechanisms of Infection 
BVDV maintains its status as a successful global, infectious pathogen due to its ability to utilize 
a variety of mechanisms to infect its host.  Like other viruses, BVDV’s primary objectives are 
to evade the host immune response, establish persistence within the host, and potentiate its 
lifecycle.  To successfully spread and persist within a host population, viruses must be able to 
alter their infection mechanisms in response to altering host factors that include the host’s 
generation time, population, and mobility (Schweizer et al., 2006).  BVDV’s global success is 
primarily due to its ability to adjust its infectious mechanism in response to these ever-changing 
factors.  These mechanisms are organized within two general strategies of host infection: the 
hit-and-run strategy and the infect-and-persist strategy (Peterhans and Schweizer, 2012). 
 The hit-and-run (or transient infection) strategy is used for the rapid synthesis of new 
viral particles and is commonly observed in such viruses as Ebola and influenza.  It is 
epidemiologically-characterised by the rapid dissemination of infection within a population 
during a short period of time and is commonly utilized by viruses that do not have efficient 
mechanisms to evade the host’s immune response.  Hit-and-run is adequate if the host 
population is large, the host has a short generation time, or the host is mobile.  However, it is 
inadequate if the virus cannot infect a new host following the death of the original host; 
therefore, cannot continue its lifecycle.  This strategy will end in either the death of the host or 
the elimination of the virus and acquisition of host immunity (Schweizer et al, 2006).  
Cytopathic BVDV strains are more likely to initiate a hit-and-run infection, the host’s survival 
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against which will depend on the strength of its immune system.  Immunocompetent cattle can 
usually eliminate a strain establishing hit-and-run within 10 – 14 days while those cattle with 
undeveloped immune systems – including fetal calves – will more likely die when BVDV 
infects in this fashion (Desport et al., 1998).    
 To avoid the risk of being unable to spread to a new host, viruses may employ an infect-
and-persist strategy, which is commonly utilized by such pathogens as herpesviruses and 
lentiviruses.  For this mechanism to succeed, viruses must evade the host’s immune system, 
often invoking elaborate mechanisms to do this to ensure they are not eliminated from the host 
(Alcami and Koszinowski, 2000; Finlay and McFadden, 2006).  The known mechanisms by 
which BVDV avoids the immune system – which will be discussed later – are mainly based on 
how it successfully prevents IFN from initiating an anti-viral state.  BVDV mainly enters its 
hosts via the infect-and-persist strategy, the non-cytopathic strains being those most likely to 
establish a persistent infection, which accounts for the greatest number of clinical cases 
(Peterhans et al., 2003; Peterhans and Schweizer, 2013).  Non-cytopathic BVDV strains 
establish the greatest population of reservoirs by infecting fetal calves.  When a pregnant dam is 
infected, her immune system may eliminate the infection, but if a virus infects the fetus prior to 
day 150 – prior to the fetus developing a competent immune system – the fetus will likely gain 
immunotolerance to the virus.  As such, it will not eliminate BVDV even after it develops its 
immune system; therefore, it will be born a viral reservoir, continuously shedding viral progeny 
throughout its life (Desport et al., 1998; Smirnova et al., 2009; Stokstad and Loken, 2002).   
Currently, the best viral management practice in preventing the entry of infected calves 
into livestock herds is to remove infected, pregnant animals.  Future development of 
therapeutics against BVDV may focus on eliminating the virus from infected fetal calves.  
However, methods to effectively identify infected calves within dams that have already 
developed immunity to the virus need to be improved. 
 
1.1.5 Transmission 
BVDV transmission occurs in one of two general patterns: vertical and horizontal.  Vertical 
transmission (transmission between mother and calf) often initiates the infect-and-persist 
strategy while horizontal transmission (transmission between animals of the same generation) 
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generally follows a hit-and-run strategy.  Four primary components affect transmission: 
infectivity (dosage and infectious route); form of external contact; period of infection; and the 
number of susceptible animals, which declines as hosts develop immunity to the virus (Haloran, 
1998; Thurmond, 2005).   
 
1.1.5.1 Forms of Transmission 
Vertical transmission often occurs when a dam that’s persistently infected by a non-cytopathic 
strain, passes the virus to the fetus when she experiences an acute infection.  When fetuses are 
infected prior to day 150 of gestation, which is before their immune systems have developed, 
they will normally survive.  However, this is not because they eliminate the virus but because 
they often just become immunotolerant to the virus (Brock et al., 2005).  Fetal infections that 
occur before day 150 of gestation will often result in abortion, stillbirth, congenital defections, 
or stunted growth; but in some cases, the calf will be born with a normal, healthy appearance 
(Thurmond, 2005).  Upon birth, persistently infected animals are known to intermittently shed 
high quantities of virus throughout their lifetime.  This is in contrast to fetal infection after day 
150 of gestation: the fetus typically has a competent immune system that is strong enough to 
eliminate the virus (Brock et al., 1991).  Horizontal transmission often leads to an acute 
infection, the severity of which can range from asymptomatic to fatal.  Animals acutely infected 
will temporarily release BVDV for roughly 7 days post-infection (Niskanen et al., 2000).   
 
1.1.5.2 Means of Transmission 
Infected animals can shed the virus via tears, saliva, urine, feces, nasal discharges, semen, and 
milk (Brock et al., 1991; Thurmond, 2005).  Susceptible cattle may also become infected via 
fomites released by BVDV-infected cattle undergoing a respiratory infection (Baule et al., 
2001).  While these natural direct routes are prevalent, transmission may also occur via other 
sources, such as insect vectors and people.  Flies can become BVDV reservoirs if they bite an 
infected cow (Tarry et al., 1991).  Additionally, researchers and clinicians contribute to 
transmission via iatrogenesis – infection during medical examination or treatment.  This often 
occurs when cattle are exposed to contaminated medical equipment (Houe, 1995).   
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1.1.6 Clinical Presentation 
Clinical responses to BVDV widely vary and often depend on the time at which infection 
occurred and the biotype.  Common symptoms include anorexia, pyrexia, diarrhea, enteric 
disease, upper respiratory disease, transient immune suppression, and fetal abortion 
(Bauermann et al., 2014; Smirnova et al., 2009).  Several, few, or none of these symptoms may 
appear following infection, which will lead to one of three outcomes – congenital persistent 
infection (CPI), mucosal disease (MD), or acute bovine viral diarrhea (ABVD); the severity of 
any of these outcomes is dependent on the viral strain, environmental stresses, and the presence 
of opportunistic pathogens (Desport et al., 1998; Smirnova et al., 2009)  
 CPI manifests postnatally following a non-cytopathic, prenatal infection of a calf prior 
to day 150 of gestation.  Some newborns exhibit growth retardation and a general inability to 
function normally while others remain asymptomatic and healthy for years.  MD also manifests 
postnatally, but as a result of a prenatal infection of both non-cytopathic and cytopathic strains, 
which is termed a “mixed” infection.  If MD manifests acutely, the infected animal will likely 
exhibit many of the aforementioned symptoms; notably exude excessive saliva and mucous due 
to the formation of ulcers within its nose and mouth.  In severe cases, the animal will die within 
days of clinical onset.  However, MD may also manifest chronically; in which case, animals 
often exhibit lameness, persistent weight loss, intermittent bouts of diarrhea, and respiratory 
disease.  These animals will often succumb to opportunistic pathogens following the weakening 
of their immune systems instead of the virus itself.  Finally, ABVD results from a postnatal 
infection by either a non-cytopathic or cytopathic strain.  ABVD often results from a hit-and-
run infection during which the animal will exhibit a potent and notable clinical response.  The 
animal will either recover within a two-week period or succumb to the infection (Bolin, 2002).  
 
1.1.7 BVDV Entry and Cellular Targets 
BVDV is naturally transmitted via the oronasal passages.  It replicates within both the mucous 
and the tonsils and disseminates through the body via leukocyte circulation (Bruschke et al., 
1998). Leukopenia (decrease in white blood cells), lymphoid reduction, and 
immunosuppression are hallmarks of acute BVDV infection; as mentioned, increase the 
susceptibility of the animal to secondary infections.  Immunosuppression is partially mediated 
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via reducing the total leukocyte number, but also by inhibiting various functions of leukocytes – 
typically lymphocytes and macrophages. These functions include reducing their chemotaxis and 
impairing both their bacterial killing and their responsiveness of innate immune sensory 
systems (Baigent et al., 2004; Charleston et al., 2001; Glew et al., 2003; Jensen and Schultz, 
1991; Kapil et al., 2005; Lamontagne et al., 1989; Liu et al., 1999; Potgieter, 1995; Schweizer 
et al., 2006).   
 While BVDV often infects during a point in fetal gestation prior to immune system 
development, it must overcome immune barriers in order to successfully infect calves after the 
immune system matures.  Considerable research has been devoted to characterising the 
interactions between BVDV and the host; in particular, on interferon (IFN)-mediated defenses.  
As viruses generally induce IFN and an IFN-mediated response, this focus is not surprising, but 
there has been ongoing debate regarding the extent to which BVDV influences this response, 
particularly with respect to non-cytopathic BVDV strains.   
 The immune system is an interactive network of cells, chemicals, and barriers that is 
involved in protecting the host from foreign substances.  It is separated into two components: 
the ever-present, unlearned, nonspecific, innate immune system and the learned, specific, 
adaptive immune system (Chaplin, 2010; Parkin and Cohen, 2001).  Before discussing the 
current knowledge of BVDV-host interaction, it is important to first review the immune system 
and discuss the role IFNs play in host defense.     
 
1.2 IMMUNE RESPONSE 
 
1.2.1 Overview of the Immune Response  
The innate immune system is the first line of defense and is comprised of physical and 
microbiological barriers; chemical effector molecules; and a variety of cells that collectively 
mediate inflammation, directly kill pathogens via phagocytosis, and coordinate additional 
immune responses through the release of cytokines (chemical messengers).  Neutrophils, 
macrophages, and dendritic cells (DCs) are the primary cellular mediators of the innate immune 
system, which collectively phagocytose foreign substances and infected cells, release pro-
inflammatory cytokines, and activate the adaptive immune system through antigen presentation.   
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 DCs liaise between the two major forms of immunity by stimulating adaptive immune 
cells using degraded antigens originally processed by innate immune cells.  DCs present 
degraded antigens via surface identity markers – major histocompatibility complexes (MHCs) – 
to T lymphocytes, a class of immune cells that facilitate the destruction of intracellular 
pathogens in a response known as “cellular immunity”.  Distinct subclasses of T lymphocytes 
perform different functions.  While more exist, cytotoxic T lymphocytes (CTLs) and helper T 
(TH) lymphocytes are the main agents of cellular immunity.  CTLs eliminate pathogen 
reservoirs – virus- or bacteria-infected cells – particularly those that evade macrophage 
destruction.  TH lymphocytes stimulate further immune responses by releasing a series of 
cytokines that activate additional T lymphocytes, additional macrophages, and B lymphocytes 
(a population of adaptive immune cells) that mediate elimination of extracellular antigens 
through the release of antibodies.  IFN-γ is a pivotal cytokine released by TH lymphocytes that 
is involved in eliminating intracellular pathogens (Chaplin, 2010; Parkin and Cohen, 2001).  
 
1.2.2 Activation of Innate Immunity 
 
1.2.2.1 Innate Immunity – Detecting Foreign Substances 
The innate immune system utilizes several structures within and on the surfaces of cells to 
detect pathogens and other foreign substances.  These structures – pattern recognition receptors 
(PRRs) – detect common structural elements that are associated with one or more groups of 
pathogens – pathogen-associated molecular patterns (PAMPs).  Effectively, PRRs do not 
specifically identify microbial, viral, or fungal pathogens, but rather identify structures to which 
these pathogens would commonly exhibit or release.  Upon identification, PRRs act as alarms 
for host cells and signal the host cells to initiate an immune response.   
 There are four known categories of PRRs.  The first two are the Toll-like receptors 
(TLRs) and the C-type-lectin receptors (CLRs), both of which are bound to extracellular or 
intracellular host cell membranes.  The other two are the RIG-I-like receptors (RLRs) and the 
NOD-like receptors (NLRs), both of which are located within the cytoplasm.  When these 
receptors detect a foreign pattern – a potential host cell threat – they initiate signalling pathways 
that lead to the synthesis and release of cytokines that respond to the detected threat.  As TLRs 
and RLRs are essential for viral detection, it will be these structures on which this thesis will 
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focus (Daigle et al., 2014; Kumagai and Akira, 2010; Medzhitov and Janeway, 2000; 
Mogensen, 2009; Takeuchi and Akira, 2010; Vance et al., 2009).  
 
1.2.2.2 Toll-like Receptors 
TLRs are primarily located on the surfaces of the extracellular plasma membrane and the 
internal endosomal membranes of monocytes, macrophages, DCs, and murine B cells.  Their 
distribution across cellular locations and types ensures that the immune system maintains 
constant surveillance for extracellular and intracellular threats (Meylan et al., 2006).  
Researchers have so far identified 13 TLRs within mammalian species and up to 20 when 
including non-mammalian species (Hansen et al., 2011).   
 Structurally, TLRs are type-I-membrane glycoproteins that are divided into an 
extracellular, leucine-rich repeat (LRR) domain; a transmembrane domain; and a cytosolic, 
Toll-interleukin-1 receptor (TIR) homology domain.  The LRR interacts with and identifies 
PAMPs of both viruses and bacteria.  This interaction triggers the TLR to send a signal through 
to its TIR domain, which transmits this signal via of a kinase-mediated pathway through the 
cytoplasm to ultimately induce the transcription of genes that are involved in mediating an 
immune response.  When the initial host cell detects a viral PAMP, most of the responsive  
genes are translated into proteins that are involved in mediating inflammation of the currently 
infected cell, as well as the neighbouring cells, in a process called “anti-viral state initiation” 
(García-Sastre and Birion, 2006; Peterhans and Schweizer, 2013).   
 As mentioned, several TLRs have been identified, which collectively respond to viral 
and bacterial PAMPs.  The classic TLR4 recognizes bacterial lipopolysaccharide (LPS) at the 
extracellular plasma membrane.  Other bacterial-recognizing PAMPs include TLR-1, -2, and -6, 
which recognize lipoteichoic acid and bacterial lipoproteins; TLR-5, which recognizes bacterial 
flagella; and TLR-9, which recognizes hypomethylated CpG DNA of both bacteria and viruses.  
TLRs that primarily recognize viral patterns include TLR-3, which recognizes dsRNA; and 
both TLR-7 and -8, which recognize ssRNA.  As such, TLR-7 and -8 would be the most 
important receptors in identifying BVDV (Aderem and Ulevitch, 2000; Kumar et al., 2009; 
Mogensen, 2009).   
 TLRs -1, -2, -4, -5, and -6 are expressed at the extracellular plasma membrane while 
TLRs -7, -8, and -9 are expressed on the internal endosomal membrane.  TLR-3 may be found 
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at both sites.  While the TLRs that detect bacterial components recognize patterns that would 
not be found within the host, the nucleic-acid detecting TLRs identify patterns that the host cell 
might produce, such as RNA.  This conflict in identifying which ssRNA structures are 
associated with the host or a pathogen is primarily reduced by the endosomal location of the 
TLRs.  Host cell nucleic acid is not normally found within compartmentalized organelles, 
except for the nucleus.  Furthermore, host nucleic acids are often methylated, which 
discriminates them from non-host nucleic acids (Bauer, 2006; Hornung et al., 2008; Ishii and 
Akira, 2005; Iwasaki and Medzhitov, 2004; Karikó et al., 2005; Vercammen et al., 2008).  
Despite its source, TLR stimulation by ssRNA initiates a strong cytokine response, particularly 
an IFN response that further activates secondary immune responses via a well-defined 
signalling network that exists in both natural killer (NK) cells and T lymphocytes, the details to 
which will be discussed later (Bekeredjian-Ding et al., 2005). 
  
1.2.2.3 RIG-I-like Receptors 
Working along with TLRs are the RLRs, RNA helicases that exist within the cytoplasm to 
observe and identify viral ssRNA and dsRNA (Kawai and Akira, 2009).  Three RLRs have so 
far been identified and include retinoic acid-inducible gene (RIG-1), melanoma differentiation 
associated factor 5 (mda-5), and laboratory of genetics and physiology 2 (LGP2).  Structurally, 
they all have PAMP-binding, C-terminal repressor domains; RNA helicase domains; and with 
the exception of LGP2, two caspase recruitment domains (CARDs).  RLRs broadly exist at low 
levels but particularly within myeloid, epithelial, and central nervous tissues.  Expression of 
these molecules drastically increases upon stimulation by viral nucleic acids or IFN (Mogensen, 
2009; Wilkins and Gale, 2010; Andrejeva et al., 2004; Yoneyama et al., 2004). 
 While these three receptors recognize non-self RNA, they have their own “preferences” 
in that they often interact with RNA based on the RNA’s characteristics.  RIG-I preferentially 
identifies foreign ssRNA that is 5’-triphosphosphorylated (5’ppp) at the ends.  Furthermore, 
RIG-I preferentially interacts with shorter dsRNA pieces with respect to mda-5 (Kato et al., 
2008).  This makes RIG-I comparatively more important than mda-5 in identifying BVDV.  
Finally, LGP2 recognizes the terminal ends of dsRNA, interacting with the foreign nucleic acid 
in a similar manner to RIG-I and mda-5.  While further research still needs to be performed to 
confirm its role, current understanding suggests LGP2 changes the structural conformation of 
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foreign RNA in such a manner that when the altered RNA subsequently interacts with the other 
two RLRs, it enhances the activation of their signalling functions (Reikine et al., 2014).  As 
with TLRs, RLR stimulation activates a strong cytokine response, which is initiated when the 
PAMP signal is carried through a well-defined signalling pathway that upregulates a series of 
inflammatory and IFN-stimulated genes (ISGs). 
 
1.2.2.4 From PRR to Immune Response 
While they signal through different intermediary proteins in their cascades, they target the same 
downstream transcription factors: AP-1, IRF3/7, and NF-κB (Peterhans and Schweizer, 2013).  
For this section, the TLR signalling discussion will be restricted to TLR7/8 due to its relevance 
to BVDV. 
 When foreign RNA interacts with TLR7/8, their extracellular domains homo- or 
heterodimerise and then send an initial signal through the TIR domain.  This initiates 
recruitment of the universal adaptor protein, myeloid differentiation primary response gene 88 
(MyD88), to that site.  After recruitment, MyD88 interacts with downstream interleukin 
receptor-associated kinases (IRAKs) 1 and 4 to form a large “signalling tower”.  This tower 
amplifies the initial signal by sending it to numerous downstream proteins (ligases, proteases, 
and kinases) to ultimately activate the previously mentioned transcription factors (Baccala et 
al., 2009; Kumar et al., 2009; Lin et al., 2010; Mogensen, 2009; Wasserman, 2010).  
 RLRs activate these transcription factors through a signalling cascade independent of 
TLRs 7 and 8.  While further research is still needed to confirm the role of LGP2, RIG-I and 
mda-5 have been shown to initiate a signalling cascade following interaction with foreign RNA.  
Upon stimulation, the CARD domains of RIG-I and mda-5 interact with the adaptor protein, 
mitochondrial antiviral signalling protein (MAVS), located on the extracellular mitochondrial 
membrane, as well as on cellular peroxisomes.  While the mechanism by which peroxisomal 
MAVS mediates downstream signalling is still unknown, mitochondrial MAVS aggregates 
following this RLR-interaction and potentiates a downstream signalling cascade.  The first set 
of kinases to be signalled are MAPK, IKK, and Tbk-1 (or IKKε), which respectively activate 
AP-1, NF-κB, and IRF3/7 (Moresco and Beutler, 2010; Satoh et al., 2010; Seth et al., 2005; 
Kawai et al., 2005; Dixi et al., 2010; Sharma and Fitzgerald, 2010; Hou et al., 2011).   
15 
 
 Whether BVDV ssRNA is sensed by TLRs, RLRs, or both types of PRRs, the three 
common transcription factors promote the expression of important genes that are involved in 
the initial immune response.  These include an assortment of pro-inflammatory cytokines, as 
well as cytokines that initiate an antiviral state: the type I interferons.  Figure 1.2 shows the 
TLR7/8 and RLR pathways, with reference to stimulation by BVDV ssRNA. 
 
Figure 1.2: Signalling cascades initiated by TLR7/8 and RLRs (RIG-1 and Mda-5).  When 
ssRNA interacts with an RLR, the receptor will activate mitochondrial MAVS, which 
stimulates multiple kinase signalling intermediates that can activate transcription factors 
IRF3/7, AP-1, and NF-κB to transcribe type I IFNs or inflammatory cytokines.  When ssRNA 
interacts with TLR7/8, it initiates the formation of a “signalling tower” that’s comprised of 
MYD88, IRAK1, and IRAK4, which activates TRAF3, TRAF6, and TAK1 to stimulate the 
same kinase intermediates to activate IRF3/7, AP-1, and NF-κB and transcribe the same genes 
as the RLR signalling cascade. 
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1.2.3 Cytokines and the Interferons  
Cytokines are essential components of the immune system and ensure efficient immune cell 
interaction.  These molecules are mainly first messengers, which bind to cell surface receptors 
and initiate a signalling cascade.  This cascade ultimately leads to the stimulation of genes, 
which translate to effector proteins, including additional cytokines.  As mentioned, viral 
PAMPs also stimulate surface or internal receptors that lead to increased expression of many of 
these genes, but also the initial cytokines that coordinate the innate immune response (García-
Sastre and Biron, 2006; McNab et al., 2015; Schneider et al., 2014).  The most influential 
cytokines involved in the response to BVDV and other viruses are the interferons. 
 “Interferon” is the name for a group of cytokines that, as the name suggests, interfere 
with or reduce the ability of viral pathogens to potentiate their infections.  Three groups of IFNs 
– type I, type II, and type III – have so far been discovered.  Type I IFNs – the best defined of 
which are IFN-α and IFN-β – are classically synthesized by virus-infected cells.  Type II IFN – 
also called IFN-γ – is synthesized by select immune cells involved in cellular immunity.  Type 
III IFNs – the IFN-λ cytokines – are also synthesized by virus-infected cells, but by a more 
limited cell population than type I IFNs.  This thesis will focus on the synthesis and the action 
of type I and type II IFNs.   
 
1.2.3.1 Type I IFNs 
Type I IFNs are often the first cytokines synthesized during viral infection.  As mentioned, viral 
nucleic acids stimulate TLRs and RLRs, which then activate AP-1, NF-κB, and IRF3/7.  These 
transcription factors cross the nuclear membrane and initiate type I IFN up-regulation.  Upon 
translation, type I IFNs initiate a series of biologic actions that are meant to establish an 
“antiviral state”.  This antiviral state is not established because these cytokines are directly 
antiviral, but rather because they activate genes that initiate an antiviral response.  Following 
their syntheses, type I IFNs are released by the infected cell and bind to receptors on the same 
infected cell and on adjacent cells to activate these genes in an autocrine and paracrine manner, 
respectively (Abbas and Lithman, 2005; Bonjardim, 2005; García-Sastre and Biron, 2006; 
Goodbourn et al., 2000; McNab et al., 2015; Randall and Goodbourn, 2008, Samuel, 2001).  
The signalling kinases through which these genes are activated are within the JAK-STAT 
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pathway, the details of which will be discussed later.  Researchers have identified more than 
100 genes that respond to type I IFNs.  Of these, the most well-known include myxovirus-1 
(Mx-1), protein kinase R (PKR), and 2’,5’-oligoadenylate synthetase (OAS)-1.  These 
interferon-stimulated genes (ISGs), once synthesized, are released to initiate autocrine and 
paracrine signalling, which collectively limits the spread of infection by inhibiting viral 
replication and translation (García-Sastre and Biron, 2006; Schneider et al., 2014; Taniguchi 
and Takaoka, 2002).   While their role in inhibiting the viral lifecycle is paramount, type I IFNs 
have other functions that strengthen immune response by linking both innate and adaptive 
immune components. 
 Type I IFNs exert their effects on well-known immune cell populations, including 
myeloid cells, DCs, B lymphocytes, T lymphocytes, and NK cells.  Their contribution to 
enhancement of the adaptive immune response begins by activating immature DCs.  Type I 
IFNs increase the expression of class I MHC molecules and such co-stimulatory molecules as 
CD80 and CD86.  Collectively, this increases the DCs’ abilities to stimulate CTLs, which 
increases the ability of the latter cell population to destroy virus-infected cells (Hahm et al., 
2005; Ito et al., 2001; Montoya et al., 2002).  Furthermore, DCs promote both CTL and TH 
lymphocyte responses.  Type I IFNs enhance the ability of TH lymphocytes to increase the 
survival and the clonal expansion of B lymphocytes, as well as promote their differentiation 
into TH1 lymphocytes and the survival of NK cells, both of which produce IFN-γ (Brinkmann et 
al., 1993; Le Bon et al., 2006; McNab et al., 2015).  Finally, IFN-α mediates the accumulation 
of lymphocytes around the lymph nodes, thereby increasing the likelihood of lymphocyte 
stimulation by antigens within the nodes (Welsh et al., 2012).   
Overall, type I IFN responses consist of two components: induction and activity.  As 
these cytokines are so important in both preventing virus spread and bolstering immune 
responses, viruses must develop ways to prevent either their induction or their biologic actions.  
Evidence has demonstrated that BVDV invokes various mechanisms to prevent both, methods 
which will be further discussed.  In addition to type I IFNs, another important IFN is involved 
in countering viral infection by promoting adaptive immune responses and bolstering innate 
immune responses – IFN-γ.  
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1.2.3.2 IFN-γ 
IFN-γ is a homodimeric protein that is an important mediator of innate immunity and (adaptive) 
cellular immunity.  It is not specifically an antiviral cytokine, but its biologic actions are crucial 
to antiviral immune response.  This cytokine is primarily released by CTLs, and TH1 
lymphocytes, but tends to first be released by NK cells.  The main status of IFN-γ is as the 
immune system’s primary macrophage-activating messenger, increasing the microbicidal 
ability of macrophages by stimulating them to transcribe genes that encode the enzymes 
responsible for activating nitric oxide and various reactive oxygen intermediates (Bonjardim, 
2005; Goodbourn et al., 2000; Lin and Young, 2013; Schroder et al., 2004). 
 IFN-γ stimulates a variety of immune cells to promote various functions.  Firstly, IFN-γ 
promotes the expression of both MHC molecules and co-stimulators on DCs to improve their 
ability to present antigens to naïve T lymphocytes; thereby, hasten adaptive immune response 
initiation (Cook et al., 1992, Schroder et al., 2004).  Upon antigen recognition, IFN-γ enhances 
the activities of both T and B lymphocytes.  More important to the viral response, IFN-γ 
induces differentiation of T cells to TH1 cells, a move that’s enhanced by the release of IL-12 – 
another TH1 promoting agent – by IFN-γ-activated macrophages (Schmitt et al., 1994).  Studies 
using murine cell lines have shown that IFN-γ also increases expression of the IL-12 receptor 
(Yoshida et al., 1994).  Furthermore, IFN-γ promotes isotype switching of B cells to specific 
subclasses that activate the complement cascade (a series of successively activated proteins that 
surround and bind (opsonise) infected cells to promote their phagocytosis) (Hasbold et al., 
1999).  These effector functions collectively promote the cell-mediated destruction of virus-
infected cells.  
Like type I IFNs, IFN-γ signals through the JAK-STAT pathway to activate a variety of 
gamma-activated sequence (GAS) genes, one of the most well-known being IRF1, a 
transcription factor responsible for, among other things, further activating Type I IFNs.  
Additional genes transcribed include signal transducer and activator of transcription (STAT)-1, 
a component of the JAK-STAT pathway; and suppressors of cytokine signalling (SOCS), 
proteins that repress IFN-γ signalling through a negative feedback loop (Lehtonen et al., 1997).  
Given their collective importance in the viral immune response, suppression of both type I IFNs 
and IFN–γ would be pivotal in order for BVDV to successfully infect its host.  In addition to 
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preventing their interaction with immune cell receptors, BVDV could also target components of 
the JAK-STAT pathway to restrict cytokine signalling. 
 
1.2.4 JAK-STAT Signalling Pathway 
 
1.2.4.1 Components of IFN Signalling 
IFNs transfer their signals through a series of STAT proteins that reside within the cytoplasm.  
They are phosphorylated by Janus kinases (JAKs) following cytokine-receptor interaction.  The 
four known JAKs include JAK-1, JAK-2, TYK-2, and JAK-3, and the seven known STATs 
include STAT-1, STAT-2, STAT-3, STAT-4, STAT-5a, STAT-5b, and STAT-6.  Collectively, 
JAK-1, JAK-2, and TYK-2 are involved in mediating IFN-α- and IFN-γ-dependent responses, 
utilizing STAT-1 and STAT-2 to further transmit the cytokines’ signals  (Shuai et al., 2003).    
 IFN-α binds to a receptor that consists of two subunits, IFNAR1 and IFNAR2, which 
cross-phosphorylate and then interact with TYK-2 and JAK-1, respectively.  The JAKs 
phosphorylate STAT-1 and STAT-2, which dimerise and translocate into the nucleus to activate 
ISGs (Welsh et al., 2012).  IFN-γ exerts a similar response.  The receptor to which the cytokine 
binds consists of IFNGR1 and IFNGR2, which cross-phosphorylate and then interact with JAK-
1 and JAK-2, respectively.  The JAKs phosphorylate two STAT-1 proteins, which dimerise and 
translocate to the nucleus to activate GAS genes (Hilton et al., 1998; Samuel, 2001).  Figure 1.3 
shows the specific pathways within the JAK-STAT network that are utilized following the 
binding of IFN-α or –γ. 
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Figure 1.3: IFN-α and IFN-γ signalling through the JAK-STAT signalling network.  IFN-α 
binds to two receptors that cross-phosphorylate and then interact with TYK-2 and JAK-1, 
which phosphorylate and initiate the dimerisation of STAT-1 and STAT-2, two transcription 
factors that stimulate the up-regulation of various ISGs.  IFN-γ binds to two receptors that 
interact with JAK-1 and JAK-2, which phosphorylate and initiate the dimerisation of two 
STAT-1 proteins that stimulate the up-regulation of various GAS genes.  
 
1.2.4.2 Negative Regulation of IFN Signalling: SOCS 
Several cellular and viral proteins have been identified as JAK-STAT pathway negative 
feedback regulators.  A well-studied group includes SOCS, the roles of which are to reduce the 
likelihood of uncontrolled inflammation.  There are eight members of the SOCS family: 
cytokine-inducible SH2 protein (CIS) and SOCS-1 through -7.  These inhibitory proteins all 
share two common features: a central SH2 domain and a conserved, 40-mer, C-terminal motif, 
which is known as the “SOCS box” (Hilton et al., 1998; Samuel, 2001).  
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 SOCS-1 and -3 are classic negative feedback regulators, repressing IFN-γ signalling 
after their expression is increased by IFN-γ.  Evidence suggests that both SOCS-1 and -3 
repress the JAK-STAT pathway at the intracellular domain of the cytokine’s receptor (Samuel, 
2001; Larsen and Ropke, 2002).  As mentioned, JAK-1 and JAK-2 phosphorylate the two 
intracellular IFNGR domains after IFN-γ binds; the intracellular domains phosphorylate two 
STAT-1 proteins, which dimerise and cross the nuclear membrane to initiate transcription of 
SOCS-1 and -3, which after translation, bind at or near the intracellular side of the receptor and 
prevent the IFN-γ signal from initiating further STAT-phosphorylation.  SOCS-1 interacts 
directly with JAK-2 while SOCS-3 interacts with the IFN-γ receptor at the phosphorylation site.  
Evidence has suggested that SOCS-3 may also interact with STAT-1 to reduce JAK-STAT 
signalling. 
 Given their role in inhibiting the JAK-STAT pathway, manipulation of SOCS could be 
advantageous to a viral pathogen.  A virus that can control the expression of SOCS could also 
control the host cell immune response.  In fact, recent studies have shown that hepatitis C virus 
(HCV) – a pathogen within the same family as BVDV – independently induced the expression 
of SOCS-3 (Persico et al., 2007).  These results were gathered from experiments in which the 
HCV core protein was overexpressed in a hepatocyte cell line.  Overexpression of these viral 
proteins caused increased SOCS-3 production, which inhibited IFN-α-signalled-STAT-1 
activation, STAT-1 nuclear translocation, and STAT-1 DNA-binding (El-Saadany et al., 2013).   
 Extensive evidence has shown that other viruses also initiate mechanisms that induce 
strong SOCS expression and inhibit antiviral immune response (Akhtar and Benveniste, 2011).  
As such, analysing both SOCS-1 and -3 is important to see if BVDV utilizes these proteins to 
reduce antiviral immune responses.    
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1.3 BVDV-HOST INNATE IMMUNE INTERACTION 
BVDV’s global success is credited to its ability in altering the mechanisms through which it 
establishes infection.  While more virulent strains commonly initiate acute infections, most 
strains, particularly non-cytopathic strains, typically establish persistent infections during fetal 
development.  BVDV has a unique and remarkable ability to bypass the adaptive immune 
system by gaining immunotolerance to both B and T lymphocytes, which is in addition to its 
ability to subvert components of the innate immune system.  Importantly, its subversion of the 
innate immune system involves inhibiting the induction of IFN (Schweizer and Peterhans, 
2001). 
 The IFN response is separated into two components: i) induction of IFN synthesis; and 
ii) activity of IFN.  This is an important distinction as IFN primarily guards uninfected cells 
against viral infection.  Most viruses, particularly those that primarily establish persistent 
infections, have developed mechanisms to inhibit induction of IFN; by extension, induction of 
an antiviral state.  These range from inhibiting the production of IFN, the activity of IFN, or the 
activity or expression of ISGs and their effector proteins.  Research has elucidated distinct 
mechanisms through which BVDV is able to avoid inducing IFN-α. 
 
1.3.1 Controversy Regarding IFN Induction 
Extensive debate has been generated regarding BVDV’s influence on the IFN defense system. 
In particular, while there is consensus on the tendency of cpBVDV strains to activate IFN 
responses, there are conflicting reports on whether similar activation of IFN-mediated 
responses occurs during infection by non-cytopathic strains.  Early in vitro infection models 
indicated that ncpBVDV isolates did not induce type 1 IFN (Adler et al., 1997; Baigent et al., 
2002; Diderholm et al., 1966; Glew et al., 2003; Nakamura et al., 1995; Schweiser et al., 2006) 
or block the induction of IFN by double-stranded RNA or other viruses (Baigent et al., 2004; 
Rossi et al., 1980; Schweiser et al., 2001).  Furthermore, it was demonstrated that fetal 
challenge with cpBVDV results in type I IFN production, whereas ncpBVDV does not, 
suggesting the ability of ncpBVDV to inhibit the induction of type I IFN to enable the virus to 
establish persistent infection early in fetal gestation (Charleston et al., 2001).  In contrast, both 
in vitro (Weiner et al., 2012) and in vivo (Brackenbury et al., 2005; Charleston et al., 2002; 
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Müller-Doblies et al., 2004; Smirnova et al., 2008; Palomares et al., 2013; Palomares et al., 
2014) acute infections with ncpBVDV induced a type I IFN response in cattle. 
 While this debate regarding induction of IFN has persisted, there seems to be a 
consensus that ncpBVDV does not interfere with the biologic activity of IFN.  This was 
assessed by treating uninfected cells with IFN prior to challenging them with ncpBVDV.  As 
IFN primarily protects uninfected cells from viral infection, the result of this challenge was that 
the IFN-treated cells were resistant to the virus (Müller-Doblies et al., 2002; Peterhans and 
Schweizer, 2013).  Conversely, when cells previously-infected with ncpBVDV were treated 
with IFN, and then further infected with other viruses (i.e. EMCV, VSV, or Sendai virus), they 
were guarded against challenge by the additional viruses.  However, the treatment with IFN 
was unable to clear the original BVDV (Schweizer et al., 2006).  This evidence suggests 
ncpBVDV avoids IFN response using a mechanism to i) avoid IFN induction; ii) resist IFN 
action; or iii) avoid interacting with IFN that’s targeting unrelated viruses.  This is novel as this 
suggests BVDV is able to establish tolerance to the innate immune system in addition to the 
adaptive immune system.  Furthermore, this suggests that persistently infected animals maintain 
their health during infection because BVDV has established tolerance to the host; not because 
the host resists the virus (Peterhans and Schweizer, 2013).   
   
1.3.2 BVDV: Known Methods of IFN Evasion 
Within the classified Flaviviridae genera, Npro and Erns are distinct to the pestiviruses and are 
thought to be involved in evasion of innate immunity, particularly in early IFN response.   
 
1.3.2.1 Npro: Reduction of Innate Immune Response 
In BVDV, Npro is needed for the separation of its N-terminus from the rest of the precursor 
polyprotein (Szymanski et al., 2009).  Evidence has shown that Npro has two functions that 
maintain viral presence and mediate infection: i) inhibit dsRNA-initiated host cell apoptosis, 
and ii) stimulate degradation – either directly or indirectly – of IRF-3, a main gene involved in 
type I IFN activation (Schneider et al., 2014).   
 While it has even been hypothesized that BVDV’s Npro actually stimulates rather than 
degrades IRF3, this hypothesis further suggests that the ability of Npro to bind to host cell DNA 
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is reduced, at least during the early stages of infection, following stimulation.  As such, BVDV 
would have at least some effect on the ability of IRF3 to activate innate immunity (Baigent et 
al., 2002; Hilton et al., 2006).  Furthermore, results gathered from one study have been used to 
suggest one mechanism by which BVDV regulates IRF3.  Npro was shown to interact with IRF3 
via virus-induced phosphorylation, an interaction that lead to polyubiquitination and  
subsequent proteasomal degradation of the protein (Chen et al., 2007).  Based on results 
gathered from studying CSFV, researchers have hypothesized that BVDV’s Npro may also 
target other host proteins.  In CSFV, Npro was shown to interact with IκB-α – a kinase involved 
in NF-κB activation – and the anti-apoptotic HCLS1-associated protein X-1 (HAX-1) protein 
(Doceul et al., 2008; Johns et al., 2010).  This has yet to be confirmed in BVDV though.  
 
1.3.2.2 Erns: RNA Degradation 
Recent research has shown Erns to be much more important in establishing immunotolerance 
than Npro.  As mentioned, Erns acts as both a structural protein and a viral RNase.  This protein is 
expressed as an envelope-attached glycoprotein, but is also secreted as a soluble protein that is 
thought to function against host immunity (Schneider et al., 1993).  Erns is capable of degrading 
both ssRNA and dsRNA molecules.  This degradative ability makes Erns a powerful IFN 
antagonist, not only because it can prevent activation of the TLR network, but because its 
secretion enables it to expand its IFN inhibition to neighbouring cells.  Erns is thought to cross 
adjacent cell membranes via receptor-mediated endocytosis.  This protein can then remain 
active for several days, degrading any RNA that would otherwise stimulate IFN.  This role as a 
decoy protein appears pivotal in establishing BVDV’s immunotolerance (Zurcher et al., 2014).   
 
1.3.3 Inducing and Responding to IFN  
As the IFNs are major mediators of initial immune responses against viral pathogens, 
elucidations of IFN evasion and repression by BVDV, particularly by non-cytopathic strains, 
are not surprising.  While evidence is further accumulating in favour of ncpBVDV establishing 
immunotolerance via bypassing this early immune response, it does not yet dispel the 
controversy regarding whether or not ncpBVDV induces IFN synthesis or response.    
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 As mentioned, while it is still debatable whether ncpBVDV induces type I IFN, current 
evidence suggests host cell ISGs respond within ncpBVDV-infected cells.  In one in vivo study, 
two groups of cattle were challenged with one of two non-cytopathic strains – the low 
virulence, SD-1, strain; and the high virulence, 1373, strain.  Expression of type I IFN genes 
and ISGs – Mx-1, OAS-1, PKR, and ISG-15 – was examined from splenic and tracheo-
bronchial lymph nodes samples.  Fold changes on day 5 of the challenge showed a statistically 
significant increase in all four genes within both challenge groups relative to the uninfected 
group.  Interestingly, no significant increase in type I IFN expression was apparent in the low 
virulence challenge group relative to the uninfected group, a result contrasted in the high 
virulence group, which only showed a significant increase in IFN-β expression.  These results 
collectively demonstrate a response by ISGs, but not a significant induction of IFN-α 
(Palomares et al., 2013).   
 If ISGs are responding during ncpBVDV infection, then it would seem logical that IFNs 
are signalling this response.  However, despite evidence showing transcriptional up-regulation 
of IFN-β in cells infected with the high virulence ncpBVDV strain, the study did not 
demonstrate transcriptional induction of type I IFNs in the low virulence strain.  Even if 
transcriptional IFN increase was established, further data showing increased translational IFN 
would have to be gathered in order to establish a proper link between induction and response.    
 While information regarding type I IFN induction is still poor, some information has 
been gathered regarding IFN-γ induction.  However, information on host cell response to IFN-γ 
is scant.  Transcriptional analyses in one study has demonstrated increased IFN-γ expression 
within the PBMCs isolated from BVDV-infected cattle, but the animals in that study were 
already immune to the virus; therefore, increased IFN-γ is anticipated (Waldvogel et al., 2000).  
Another study summarized results from experiments that examined the presence of IFN-γ 
within the amniotic fluid and blood, in addition to downstream activation of IFN-γ pathways 
within lymphoid tissues of uninfected, persistently-infected, and transiently-infected fetal 
calves.  The results showed that IFN-γ was synthesised within both the persistently and 
transiently infected fetuses.  This report became the first to identify IFN-γ increases during 
establishment of ncpBVDV persistent infection (Smirnova et al., 2014).   
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 Attempting to answer some of the more puzzling questions, this thesis examined the 
responses of ncpBVDV2-1373-infected, pregnant cattle, with priority on defining induction of, 
and responses to IFN-α and IFN-γ.  Serum IFN-α and –γ were assessed to examine induction of 
immune response while expression of genes that classically respond to either cytokine, along 
with signalling behaviour of the JAK-STAT network, were examined within peripheral blood 
mononuclear cells (PBMCs) to determine the patterns of response to the synthesised IFNs.  
Furthermore, correlations between the magnitude of these responses and disease outcomes were 
performed in order to determine if the animals were responding to the IFNs.  Overall, these 
assessments were correlated with outcomes of disease to see what may have led to or what may 
have characterised a severe infection and a manageable infection.  
 
1.4 RATIONALE, HYPOTHESIS, AND OBJECTIVES 
 
1.4.1 Hypothesis 
Infection by ncpBVDV2-1373 will initiate both the syntheses and biologic activities of IFN-α 
and IFN-γ. 
 
1.4.2 Overall Objective 
To examine the induction of IFN-α and -γ and the expression of select genes that classically 
respond to these cytokines during the first 10 days of an in vivo ncpBVDV2-1373 challenge of 
pregnant cattle. 
 
1.4.3 Specific Objectives 
1. Challenge animals and monitor the induction of IFN-α and -γ, as well as the induction 
of clinical responses. 
2. Monitor the induction of functional IFN-α and -γ responses, including the JAK-STAT 
signalling pathway and classic interferon-stimulated genes (ISGs). 
3. Identify correlations between immune system induction and response in both cattle that 
are severely and non-severely infected by BVDV. 
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2. MATERIALS AND METHODS 
 
2.1 Reagents 
The names of the materials used in this project, their suppliers, and the suppliers’ addresses are 
listed in Table 2.1.   
 
Table 2.1: List of materials and suppliers 
Reagent/Chemical Supplier 
Acetic Acid VWR 
Acetonitrile EMD Biosciences, VWR 
Adenosine triphosphate (ATP) New England Biolabs 
Streptavidin alkaline phosphatase Jackson ImmunoResearch 
Aprotinin Sigma-Aldrich 
Beta-glycerophosphate Sigma-Aldrich 
Bovine serum albumin Sigma-Aldrich 
Brij-35 ICN Biomedicals 
Chloroform, with amylene stabilizer, ≥ 99% Sigma-Aldrich 
Diethanolamine Sigma-Aldrich 
Ethyl alcohol, 95%  Greenfield Specialty Alcohols Inc. 
Ethylene glycol tetraacetic acid (EGTA) Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich 
Fetal bovine serum Life Technologies  
Gelatin from cold water skin fish Sigma-Aldrich 
Gentamycin Bio Basic Canada Inc. 
Glycerol, 50% GE Healthcare 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
Life Technologies  
Horse serum Life Technologies 
iCycler iQ PCR plates Bio-Rad Laboratories Inc. 
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IFN-α VIDO-InterVac 
IFN-γ Novartis 
Immulon 2 96U plate Thermo Fisher Scientific 
Isopropyl alcohol Sigma-Aldrich 
Lab-Tek chamber slide (4-well) Thermo Fisher Scientific  
Leupeptin Sigma-Aldrich 
Magnesium chloride hexahydrate EMD Biosciences 
Microseal B plates Bio-Rad Laboratories Inc. 
Minimal Essential Media (MEM) Sigma-Aldrich 
Non-essential amino acids Life Technologies  
Para-nitrophenylphosphate (PNPP) Sigma-Aldrich 
Percoll GE Healthcare 
Phenylmethylsulphonyl fluoride (PMSF) Sigma-Aldrich 
Phosphate-buffered saline (PBS) VIDO-InterVac 
PNPP buffer VIDO-InterVac 
Sodium acetate Sigma-Aldrich 
Sodium chloride Sigma-Aldrich 
Sodium fluoride Sigma-Aldrich 
Sodium pyrophosphate Sigma-Aldrich 
Sodium pyruvate Life Technologies  
Sodium vanadate Sigma-Aldrich 
Sterile Water Life Technologies 
Streptavidin alkaline phosphatase Jackson ImmunoResearch 
SYBR Green Supermix Bio-Rad Laboratories Inc. 
Tris Sigma-Aldrich 
Triton-X Sigma-Aldrich 
Trizol LS Life Technologies  
Trypsin Bio Basic Canada Inc. 
Tween-20 Sigma-Aldrich 
29 
 
Versene VIDO-InterVac 
Cell Lines Supplier 
Madin-Darby Bovine Kidney (MDBK) cell 
line 
VIDO-InterVac 
Antibodies Supplier 
Biotin-Goat Anti-Rabbit IgG (H+L) DS Grade Life Technologies  
Mouse anti rBoIFN-α monoclonal antibody, 
E2-1C6 
VIDO-InterVac 
Mouse anti rBoIFN-α monoclonal antibody, 
D5-1D10 
VIDO-InterVac 
Mouse anti rBoIFN-γ monoclonal antibody, 2-
2-1A 
VIDO-InterVac 
Rabbit anti BoIFN-α  VIDO-InterVac 
Rabbit anti BoIFN-γ  VIDO-InterVac 
Rabbit BVDV type 2 E2 antibody VIDO-InterVac 
ReserveAPTM phosphatase-labeled goat anti-
rabbit IgG (H+L)  
KPL 
Kits Supplier 
Alkaline-Phosphatase Conjugate Substrate Kit Bio-Rad Laboratories Inc. 
Superscript® III SuperMix for qRT-PCR Life Technologies 
Supplier Supplier Address 
Bio-Rad Laboratories Inc. Mississauga, ON, Canada 
Bio Basic Canada Inc. Markham, ON, Canada 
EMD Biosciences Mississauga, ON, Canada 
GE Healthcare Baie d’Urfé, PQ, Canada 
Greenfield Specialty Alcohols Inc. Brampton, ON, Canada 
ICN Biomedicals St. Laurent, PQ, Canada 
Jackson ImmunoResearch West Grove, PA, USA 
KPL Guelph, ON, Canada 
Life Technologies Burlington, ON, Canada 
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New England Biolabs Pickering, ON, Canada 
Novartis Mississauga, ON, Canada 
Sigma-Aldrich Oakville, ON, Canada 
Thermo Fisher Scientific Whitby, ON, Canada 
VIDO-InterVac Saskatoon, SK, Canada 
VWR St. Catharines, ON, Canada 
 
 
2.2 BVDV Challenge and Clinical Evaluation 
Two groups of Angus-Aberdeen cross-bred heifers, identified as Group A (n = 8) and Group B 
(n = 14), were screened via ear notch extract and ELISA (Idexx) to confirm negative results for 
BVDV, bovine herpes virus, and bovine respiratory syncytial virus. The heifers were 
inseminated at one-year-old and confirmed pregnant via ultrasound.  At Day 80 of pregnancy, 
Group B cows were intranasally infected with ncpBVDV2-1373 (TCID50 = 107.2) while Group 
A cows were kept uninfected during the duration of the trial.  
 
2.3 Body Weight and Temperature 
Body weight and temperature measurements of the group B animals were taken daily during the 
challenge period between 9 AM and 12 PM by the Animal Care staff of VIDO-InterVac. 
 
2.4 Serum and Peripheral Blood Mononuclear Cell (PBMC) Isolation 
For the following isolation, all PBS that was used contained 140 mM NaCl, 2.7 mM KCl, 7.0 
mM Na3PO4, and 1.5 mM KH2PO4, and was set to a pH of 7.3.  50 mL of blood were extracted 
from each animal using a 60-mL syringe that contained 2 mL of 7.5% EDTA (Sigma-Aldrich).  
The blood was transferred to a 50-mL polypropylene tube and centrifuged at 1400 x g, at 20°C, 
for 20 minutes.  The PBMC layer from the centrifuged sample was collected and combined 
with room temperature 0.1% EDTA in PBS up to a volume of 35 mL.  This volume was layered 
onto 15 mL of 54% Percoll (GE Healthcare) in PBS, which was then centrifuged at 2000 x g, at 
20°C, for 20 minutes.  The PBMC layer was collected and combined with cold PBS.  The cells 
were centrifuged at 300 x g, at 4°C, for 8 minutes; after which, the supernatant was removed, 
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and the cells were resuspended.  This step was repeated twice, with the third centrifugation 
being run at 150 x g.  Before the third centrifugation, the pellet was resuspended in 10 mL of 
PBS, 100 μL of which was removed for cell counting via the trypan blue exclusion method 
(Strober, 1997).  After the third centrifugation, the supernatant was removed and 5 x 106 cells 
were resuspended in 250 μL of PBS.  This was combined with 750 μL of Trizol LS (Life 
Technologies) and frozen at -80°C for future gene expression analyses.  After centrifugation at 
1400 x g within the previous steps, 800 μL of serum was transferred to a 96 deep-well plate, 
which was stored at -20°C for future ELISAs.  
 
2.5 White Blood Cell (WBC) Isolation 
5 mL of blood from each cow was combined with 9.5 mL of a lysis buffer (124 mM NH4Cl 
(Sigma-Aldrich) and 34.6 mM Tris (Sigma-Aldrich), pH 7.2).  The red blood cells were lysed 
for three minutes before the samples were centrifuged.  After removing the supernatant, the 
pellet was resuspended with 10 mL of PBS and centrifuged.  The supernatant was poured off 
and the pellet was resuspended in 1 mL of 1% HEPES in minimum essential medium (MEM) 
(Sigma-Aldrich, Life Technologies).  All centrifugations were performed at 300 x g, at 4°C, for 
10 minutes.  The samples were stored at -80°C for future analyses.    
 
2.6 Viral Titration 
For this immunocytochemistry protocol, the following conditions were applied unless otherwise 
specified.  All reagents were added at 100 μL per well to a round-bottomed plate (Thermo 
Fisher Scientific).  All incubations occurred at room temperature on the benchtop.  
 
2.6.1 Growth and Infection of Madin-Darby Bovine Kidney (MDBK) Cells 
Nasal and WBC samples from each challenged animal were assessed for viral presence on days 
3, 7, and 10 post-challenge, as well as day -1 pre-challenge.  Madin-Darby Bovine Kidney 
(MDBK) cells were grown in 10% fetal bovine serum (FBS) in MEM (Life Technologies, 
Sigma Aldrich) in T150 flasks, counted using a haemocytometer, and diluted to a suspension of 
2.5 x 105 cells/mL.  100 μL of cells were then added to each well of a 96-well flat-bottomed 
plate at 2.5 x 104 cells per well.  The cells were grown overnight at 37°C.  Serial 2-fold 
32 
 
dilutions of the nasal and WBC samples were made in a separate plate.  Dilutions of pure virus 
stock served as positive controls.  The medium was removed from the cells and replaced with 
100 μL of sample from the corresponding wells of the dilution plates.  The now-infected cells 
were incubated at 37°C for 1.5 hours; after which, 100 μL of 2% FBS in MEM was added to 
each well.  They were then incubated at 37°C for 96 hours. 
 
2.6.2 Immunocytochemistry 
Following the 96-hour incubation, the cells were stained to identify the presence of BVDV.  
The cells were first blocked with 10% horse serum in MEM and incubated for 10 minutes.  The 
medium was then removed and the cells were fixed with a mixture of 75% ethanol (Greenfield 
Alcohols Inc.) and 25% acetic acid (VWR) for 10 minutes.  After fixation, the cells were 
washed thrice with 0.05% Tween 20 in PBS (PBST) (Sigma-Aldrich) and then permeabilized in 
0.01% Triton X (Sigma-Aldrich) in PBS for 20 minutes.  The wash was then repeated with 
PBST.  Rabbit BVDV Type 2 E2 antibody (VIDO-InterVac) was diluted 1:500 in PBS, and 
added to each well.  The plates were incubated for 1.5 hours and then washed.  Alkaline 
phosphatase (AP)-conjugated goat anti-rabbit IgG (KPL) was diluted 1:500 in PBS and added 
to the plates, which were incubated.  The cells were washed and then stained using an AP 
staining kit (BioRad).  Staining was indicative of viral infection; therefore, of a positive result. 
 
2.7 ELISAs 
For the following ELISA protocols, the following conditions were applied unless otherwise 
specified.  All reagents were added at 100 μL per well to an Immulon 2 96U plate (Thermo 
Fisher Scientific).   All incubations occurred at room temperature on the benchtop for one hour.  
0.05% Tween 20 in Tris-buffered saline (TBST) (Sigma-Aldrich) was used 5 x for each 
washing step.  All reagent dilutions were made in 0.1% fish gelatin in TBST (Sigma-Aldrich). 
 
2.7.1 IFN ELISAs 
ELISAs for IFN-γ (Baca-Estrada et al., 1995) and IFN-α (Hughes et al., 1994) were carried out 
as previously described.  To quantify IFN-γ, a plate was coated with mouse anti-rBoIFN-γ 
monoclonal antibody (Clone 2-2-1A) (VIDO-InterVac), diluted 1:8000 in 50.0 mM bicarbonate 
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buffer (Sigma-Aldrich), incubated at 4°C overnight, and then washed.  Serially-diluted bovine 
IFN-γ standards (Novartis AG), starting from 1 ng/mL, as well as undiluted serum samples, 
were added to the plate and incubated for two hours.  Rabbit anti-BoIFN-γ (Clone 92-132) 
(VIDO-InterVac) was diluted 1:5000, added to the plate, and incubated, followed by biotin-goat 
anti-rabbit IgG (H + L) (Life Technologies) diluted 1:10000.  Streptavidin alkaline phosphatase 
(Jackson ImmunoResearch) in 50% glycerol was diluted 1:5000, added to the plate, which was 
then incubated.  Para-nitrophenylphosphate (PNPP) (Sigma-Aldrich) was diluted in a buffered 
solution comprised of 105 mM diethanolamine (Sigma-Aldrich) and 0.5 mM MgCl2·6H2O 
(EMD Biosciences) to a final density of 1 mg/mL and added to the plate, which was incubated 
for 20 minutes.  The plates were washed with PBST between each incubation step.  Optical 
density readings (405 nm read; 490 nm reference) of the standards were used to construct a 
standard curve from which the concentrations of IFN-γ in the serum samples were calculated.  
IFN-α was detected according to the same protocol, but by using the following reagents: anti-
rBoIFN-α (Clones E2-1C6 and D5-1D10) (VIDO-InterVac) monoclonal antibodies to coat the 
plate, bovine IFN-α standards (VIDO-InterVac) to construct the standard curve, and rabbit anti-
BoIFN-α (Clone 92-133) (VIDO-InterVac) as the primary antibody. 
 
2.8 Gene Expression Analysis 
 
2.8.1 RNA Extraction 
All incubations took place at room temperature, unless otherwise specified.  The Trizol-frozen 
cell samples were thawed in their Eppendorf tubes.  200 μL of chloroform (Sigma-Aldrich) 
were added to the samples.  They were then mixed by inversion for 30 seconds and 
subsequently incubated for 3 minutes.  This mixture was centrifuged at 12 000 x g for 15 
minutes in order to separate the Trizol layer from the aqueous layer.  After centrifugation, the 
aqueous layer was collected and combined with 500 μL of isopropyl alcohol (Sigma-Aldrich).  
The sample was mixed by inversion and incubated for 10 minutes.  After incubation, the sample 
was centrifuged at 12 000 x g for 10 minutes to pellet the RNA.  After centrifugation, the 
supernatant was removed; 1 mL of 70% ethanol (Greenfield Specialty Alcohols, Inc.) was 
added to the pellet.  The pellet was suspended, mixed by inversion, and then centrifuged at 7 
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500 x g for 5 minutes.  After centrifugation, the supernatant was poured off, the Eppendorf tube 
was inverted, and the pellet was allowed to air dry for at least 20 minutes.  After air drying, 40 
μL of sterile water (Life Technologies) was added to the pellet; the tube was placed in a water 
bath at 55°C for 5 minutes.  After 5 minutes, the dissolved RNA was mixed via pipetting before 
being placed back into the water bath for another 5 minutes.  Afterwards, 2 μL of dissolved 
RNA was used to determine the concentration (ng/μL) via bioanalysis while the remaining 
sample was frozen at -80°C until cDNA synthesis was performed.   
 
2.8.2 cDNA Synthesis 
Using solutions from the Superscript III SuperMix kit (Life Technologies), RNA samples were 
reverse-transcribed to cDNA at a quantity of 500 ng.  The RNA sample was thawed from -
80°C.  Using the concentration assessed in 2.8.1, 8 μL of sterile, water-diluted RNA was 
combined with 10 μL of Reaction Mix (Buffer) and 2 μL of Enzyme Mix to a final volume of 
20 μL in a PCR Thin Wall Tube (BioRad).  The tube was placed in a thermocycler; cDNA 
synthesis commenced for 80 minutes under the following conditions: 25°C for the first 5 
minutes, 60°C for the following 60 minutes, and 70°C for the final 15 minutes.  Following 
synthesis, the cDNA was diluted 3-fold in sterile water to a final volume of 60 μL.  The sample 
was then stored at -20°C until qRT-PCR was performed.   
 
2.8.3 qRT-PCR  
3 μL of cDNA was combined with 9 μL of iQ SYBR green reaction mix (BioRad) and 3 μL of 
3.3 μM of forward-and-reverse primer pair mix to a final volume of 15 μL.  Each sample at this 
volume was added to one well of a 96-well PCR plate (BioRad) and covered with a Microseal 
cover (BioRad).  The plate was placed in a BioRad iCycler; the qRT-PCR amplification is set to 
the following parameters in Table 2.2:  
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Table 2.2: Amplification cycle for cDNA samples. 
Cycle Step Temperature (°C) Time (min.) 
1 (x1) 1 55 2:00 
2 (x1) 1 95 8:30 
3 (x45) 1 95 0:15 
2 58 0:30 
3 72 0:30 
4 (x45) 1 55 0:10 
  
 Duplicate threshold cycle values (TCVs) for each gene of a particular sample were 
averaged and assessed against the average, duplicated β-actin TCVs of the same sample using 
the following series of steps. 
 Firstly, the difference between the average TCV of a particular gene against the average 
TCV of β-actin was calculated on Day -1.  This same calculation was performed on day 3, day 
7, and day 10 of the challenge.  Afterwards, the TCV difference calculated on day -1 was 
subtracted separately from each of the TCV differences of days 3, 7, and 10.  Finally, fold 
change values for each gene were calculated by setting the negative value of these double-TCV 
differences to a base-2 exponent.  A fold change of 1 indicated no difference in gene expression 
relative to day -1.  Fold changes less than 1 indicated reduced gene expression relative to day -
1.  Fold changes greater than 1 indicated an increased gene expression relative to day -1. 
 
2.9 Variance Analysis 
To assess the statistical significance of the variation in temperatures between the surviving and 
the perishing Group B animals, a non-parametric variance test was used to complement the 
median data: the Wilcoxon Rank Sum Test (WRST). Firstly, values for temperature change 
from days 1 to 10 were summed for all animals.  Following summation, each animal was given 
a rank within a range of 1 through 14, as there are 14 animals under analysis.  The animal with 
the lowest rank had the highest temperature sum across the 10 days while the animal with the 
highest rank had the lowest temperature sum.  WRST was then performed.   
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2.10 Kinome Analysis 
All reagents are from Sigma-Aldrich and all incubations occurred at room temperature unless 
otherwise specified.  Experiments involving staining of the peptide arrays were all performed 
on the same day to minimise technical variance.  
 
2.10.1 Peptide Array Design and Construction 
Design, construction and application of the peptide arrays were performed using a modified 
version of a previously described protocol (Jalal et al., 2009).  The arrays were fabricated by a 
commercial provider (JPT Peptide Technologies, Berlin, Germany; http://www.jpt.com) and 
were designed to include peptides representing phosphorylation events from a wide variety of 
signaling pathways.  Specifically, the array included nine technical replicates of each of the 297 
unique peptides giving a total of 2 673 spots on the array.  Each peptide was 15 amino acids in 
length and had a central residue known to be phosphorylated in vivo.  A complete description of 
the array, including the coordinates of the spots and the sequence of each peptide is described 
elsewhere (Jalal et al., 2009).  
 
2.10.2 Peptide Array Staining 
Isolated PBMCs obtained on days 3, 7, and 10 post-challenge, as well as day -1 pre-challenge, 
were thawed and then lysed using 100 µL of lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM 
sodium chloride, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM ethylene glycol 
tetraacetic acid (EGTA), 1% TRITON® X-100, 2.5 mM sodium pyrophosphate, 1 mM sodium 
vanadate, 1 mM sodium fluoride, 1 µg/mL leupeptin, 1 g/mL aprotinin, 1 mM 
phenylmethylsulfonyl fluoride (PMSF)).  The cells were incubated on ice for 10 minutes and 
then centrifuged at 1000 x g, at 4°C, for 10 minutes.  A 70-µL aliquot of the resulting 
supernatant was combined with 10 µL of activation mix (50% glycerol (GE Healthcare), 50 µM 
adenosine triphosphate (ATP) (New England Biolabs), 60 mM magnesium chloride, 0.05% v/v 
Brij-35 (ICN Biomedicals), 0.25 mg/mL bovine serum albumin (BSA), 2 Ci/L γ32P-ATP) and 
incubated on a custom-designed bovine peptide array (JPT) at 37°C for 2 hours.  The arrays 
were then washed once with Tris-buffered saline (TBS), pH 7.3 containing 1% TRITON® X-
100.  Following this wash, the arrays were submerged in Pro-Q Diamond Phosphoprotein gel 
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stain (Life Technologies) and agitated for one hour.  Following the wash, the arrays were 
washed twice with 50 mL of destain (20% acetonitrile (EMD Biosciences) and 50 mM sodium 
acetate at pH 4.0) for 10 minutes each.  New destain was used for each wash.  The arrays were 
then washed with ddH2O before being dried.    
 
2.10.3 Peptide Array Scanning 
After drying, the arrays were read using a GenePix Professional 4200A microarray scanner 
(MDS Analytical Technologies, Toronto, ON) at 532 nm.  Array images were taken with a 
camera that was controlled using GenePix 6.0 software (MDS).  For each array, the signal 
intensity for each peptide was collected.  The parameters at which each intensity value was set 
include the following: 65535 scanner saturation level, local feature background set to calculate 
the background, analysis using signal mean and background mean intensity values, local 
background features excluding 2 pixels, and background width set to three feature diameters.   
 
2.10.4 Statistical Analysis: PIIKA 2 
Using a program called Platform for Intelligent, Integrated Kinome Analysis (PIIKA) 2 (Trost 
et al., 2013), a variety of statistics were generated following a previously developed pipeline 
(Li, et al., 2012).  
 
2.10.4.1 Data Pre-processing 
For all peptide spots on a particular array, actual intensity values were calculated by subtracting 
the background intensity values from the foreground intensity values.  This intensity difference 
was converted using a variance stabilization (VSN) method (Huber, et al., 2002), which 
maintained the structure of the data while adjusting it to a positive scale.  This alleviated mean-
dependent variance.  Additionally, cross-experimental data were assembled on the same scale 
in order to compare arrays between different cell treatments; in this case, control and infected.  
To make subsequent analyses easier to examine, the dataset was reassembled such that each 
row consisted all of the replicates related to a specific peptide.  The R software environment 
(www.r-project.org) function vsn2 from the vsn package was used for the VSN method (Huber, 
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et al., 2003).  Replicates were kept as separate values in all subsequent analyses, but averaged 
for clustering analysis (Everitt, 1974; Hardigan, 1975).  
 
2.10.4.2 Spot-Spot Variability Analysis 
A chi-squared (χ2) test was performed to assess the variability of replicates for each specific 
peptide on the array: the technical replicates (Draghici, 2003).  The null hypothesis (Ho) for 
each peptide stated that there was no difference in the intensities of the technical replicates, 
while an alternative hypothesis (HA) claimed that there was significant variation between the 
technical replicates.  The peptides with p-values greater than 0.1 were considered inconsistently 
phosphorylated across the array replicates.  A confidence level of 90% was used to keep as 
much data as possible.  The p-value was calculated using the R function, pchisq, from the stats 
software package. 
  
2.10.4.3 Subject-Subject Variability Analysis 
Following background subtractions of biological data, subject-subject variability analysis was 
performed and applied to datasets.  For this, an F test was performed on each peptide to 
determine if there were significant differences between infected cattle.  Data for inconsistently 
phosphorylated peptides were removed from further analyses.  
  
2.10.4.4 Treatment-Treatment Variability Analysis 
Those peptides identified as having consistent response patterns to multiple treatments across 
the same replicates were analysed via one-sided paired t-tests.  T-tests were performed to 
compare the intensities of the peptides under treatment to the intensities of the same peptides 
under control conditions. 
 As a result, two p-values were calculated for each peptide: one related to the differential 
phosphorylation of each peptide and the other to the dephosphorylation of each peptide.  Those 
peptides having a p-value lower than the defined cut-off (i.e. 0.1) were identified as 
differentially dephosphorylated and used for additional analyses.  To keep as much data as 
possible, the p-value was not adjusted.   
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 A paired t-test was conducted in order to acknowledge the interdependence between the 
peptides of both the control and treatment conditions, and was performed via the R 
environmental function t-test of the stats package, in which paired = True.  Of significance was 
that the t-test could account for the variability across the peptide replicates; therefore, those 
replicates with a significant p-value assessed via χ2 tests had insignificant p-values from the t-
test automatically.  However, this was not applicable to datasets with numerous subjects as 
significant variation for a specific peptide across these subjects under a given treatment might 
have been biologically relevant.  As such, the analysis may have been confounded if the 
peptides were statistically examined as if they were all from the same source.  
 
2.10.5 Pathway Analysis 
Peptides that are differentially phosphorylated can be utilized within a software platform called 
InnateDB (Lynn et al., 2008).  As this software uses fold changes as input values, fold changes 
were calculated as the differences between variance-stabilized normalization-transformed 
intensities of the control and the treatment.  
 Fold change, in addition to one of the p-values obtained from the one-sided t-test for 
each peptide on the array (with the exception of those peptides that were removed previously: 
Section 2.10.4.3), represented the complete InnateDB input.  If fold change was positive, then 
the p-value associated with “phosphorylation” was used.  If the fold change was negative, then 
the p-value associated with “dephosphorylation” was used.   
 Thresholds (cut-off values) associated with fold changes and p-values were set prior to 
calculation: fold change was set > 1 and p-value was set < 0.10.  Peptides that were 
respectively below or above these thresholds were removed from InnateDB analysis. 
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3. RESULTS 
The immune response of cattle to BVDV was examined.  These included identifying the 
relative levels of virus in their WBCs and nasal passages, tracking the changes in their 
temperatures and body weights, examining the levels of IFN-γ and IFN-α in their sera, and 
analysing the expression of several genes, including STAT-1, OAS-1, Mx-1, SOCS-1, and 
SOCS-3, within their PBMCs.   
 Some of the (the infected) Group B animals died during the challenge while others 
survived.  As such, the animals that died and those that survived were classified into subgroups 
of group B animals, which were labelled Group B(D) and Group B(S), respectively.  
Throughout the results, trends between (the uninfected) Group A, Group B, Group B(S), and 
Group B(D) were compared and assessed for statistical difference. 
  
3.1 Viral Presence 
To determine the efficiency of viral infection, a semi-quantitative assessment of BVDV 
presence in both nasal samples and WBCs was performed, the results of which are displayed in 
Table 3.1.  For each well of the eight rows in which the sample was diluted, presence was 
assessed as “+”, “++”, or “+++”, while lack of presence was assessed as “–”.  If wells on the 
plate were stained within rows 1 – 3, that sample was given a “+” or low rating.  If wells on the 
plate were stained up to rows 1 – 6, that sample was given a “++” or moderate rating.  If wells 
on the plate were stained up to rows 7 – 8, that sample was given a “+++” or high rating. 
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Table 3.1: Semi-quantitative assessment of viral presence in WBC and nasal samples obtained 
from all animals on days -1, 3, 7, and 10.  No viral presence (–).  Low viral presence (+).  
Moderate viral presence (++).  High viral presence (+++).  For ease of distinction, low, 
moderate, and high presence are coloured blue, green, and red, respectively. 
Group Animal WBC Viral Loads Nasal Viral Loads 
Day -1 Day 3 Day 7 Day 10 Day -1 Day 3 Day 7 Day 10 
A 24 – – – – – – – – 
A 28 – – – – – – – – 
A 33 – – – – – – – – 
A 37 – – – – – – – – 
A 41 – – – – – – – – 
A 46 – – – – – – – – 
A 51 – – – – – – + – 
B (S) 27 – – ++ +++ – – +++ +++ 
B (S) 30 – – ++ – – + ++ ++ 
B (S) 32 – – + – – – – +++ 
B (S) 42 – – + – – – ++ ++ 
B (S) 43 – – ++ + – – ++ ++ 
B (S) 44 – – + + – + ++ ++ 
B (S) 48 – – + + – – +++ +++ 
B (S) 49 – – ++ – – + ++ + 
B (D) 23 – – ++ + – – ++ +++ 
B (D) 26 – – ++ – – + ++ ++ 
B (D) 31 – – +++ + – – +++ +++ 
B (D) 36 – – ++ + – – + +++ 
B (D) 45 – – ++ ++ – + +++ +++ 
B (D) 50 – – +++ +++ – – +++ +++ 
 
 This temporal virus titration confirmed that all Group B animals were successfully 
infected with ncpBVDV2-1373.  The virus was first detected in the nasal samples, with five of 
the fourteen group B animals exhibiting positive results on day 3 and all group B WBC samples 
exhibiting viral presence by day 7.   
 Of the animals that eventually died, there is a trend of increased viral presence in their 
nasal samples.  On day 7, 25% of the group B(S) animals reached the highest score, while 50% 
of the group B(D) animals reached the highest score.  Furthermore, on day 10, 38% of the 
group B(S), in contrast to 83% of group B(D), reached the highest score. 
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3.2 Mortality 
During the challenge, six of fourteen group B animals died as a result of infection while all 
uninfected, group A animals survived.  Other reports have also shown that challenging with 
other virulent BVDV2 strains led to severe clinical disease with a high mortality rate (Bolin and 
Ridpath, 1992; Brock et al., 2007; Ellis et al., 1998; Liebler-Tenorio et al., 2003a,b).  
   
3.3 Clinical Scores 
Temperature and body weight data were only available for the group B animals during the 
challenge.  It was assumed that the temperatures of the group A animals would remain 
relatively constant across the 10-day period; possibly deviating by a maximum of 0.5°C as a 
result of normal circadian rhythm temperature fluctuation (Peedel et al., 2012).  As the animals 
were pregnant, it was also assumed that their body weights would continually increase over this 
same period.  
 
3.3.1 Temperature Change 
To more accurately track the influence of the virus during the course of infection, differences in 
temperature were taken relative to day 0.  The value for each day represents the subtraction of 
the actual temperature on that day by the actual temperature on day 0.   
 There was a notable spike in temperature between 2 and 3 days post-challenge 
followed by a second period of increased temperature roughly 7 days post-infection.  The 
magnitude and temporal aspects of these elevated periods of temperature changes have been 
previously demonstrated in other BVDV challenges (Ellis et al., 1998; Liang et al., 2006; 
Snider et al. 2014; van Drunen Littel-van den Hurk et al., 2013).  Temperature changes in both 
the group B(S) and group B(D) animals were separated and presented individually in Figures 
3.1A and 3.1B, respectively.  Additionally, the median trends of each of these groups are shown 
in Figure 3.1C.  While there was an apparent trend toward higher temperatures among animals 
that did not survive infection, the differences between groups B(S) and B(D) were not 
statistically different, i.e the p-value obtained from WRST was greater than 0.05.  
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A      B      
        
C 
 
Figure 3.1: Temperature changes in the challenged cattle with respect to day 0.  A. Individual 
data for group B(S) animals (n = 8).  B. Individual data for group B(D) animals (n = 6).  C. 
Median data for group B(S) and group B(D) animals. 
 
 Table 3.2 provides a visual representation of the temperature ranks that were used to 
compute the p-value for the animals in Group B and shows that increased temperature favours 
increased likelihood of mortality.  The top two temperature responders and four of the top five 
temperature responders were within group B(D), illustrating the trend towards higher 
temperature of animals that succumb to acute, BVDV infection.   
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Table 3.2: Temperature change ranks for all group B animals based on the summation of the 
temperatures (i.e. rank sum analysis) from days 1 to 10 of the challenge.  1 = highest 
temperature summation.  14 = lowest temperature summation.  Animals were assigned ranks (1 
– 7) if their sums were in the top half of this ranking order.  Animals were assigned ranks (8 – 
14) if their sums were in the bottom half of this ranking order. 
Group Animal Label Rank 
B(S) 27 5 
B(S) 30 7 
B(S) 32 9 
B(S) 42 8 
B(S) 43 10 
B(S) 44 3 
B(S) 48 13 
B(S) 49 14 
B(D) 23 11 
B(D) 26 1 
B(D) 31 5 
B(D) 36 12 
B(D) 45 2 
B(D) 50 4 
 
 The results in Table 3.2 illustrate that animals with high temperature ranks generally 
survived the challenge while animals with low temperature ranks generally did not survive the 
challenge.  
 
3.3.2 Body Weight Change 
As with temperature change, differences in body weight were determined relative to day 0. 
Within all animals, there was a consistent trend for reduction in body weight relative to the day 
of challenge.  Body weight changes of both group B(S) and group B(D) animals were separated 
and presented individually in Figures 3.2A and 3.2B, respectively.  Additionally, median trends 
of these groups were presented in Figure 3.2C.  Despite a noticeable trend distinguishing the 
body weight changes between groups B(S) and B(D), the two subgroups were not statistically 
distinct, i.e. the p-value obtained from WRST was greater than 0.05.  However, there was one 
animal that notably stood out in group B(S), exhibiting substantial weight loss relative to the 
other animals, as seen in Figure 3.2A.  Additionally, there was one notable animal within group 
B(D) that didn’t follow the trend of weight loss observed in the other animals, as seen in Figure 
3.2B. 
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A      B 
     
C 
 
Figure 3.2: Body weight changes in the challenged cattle with respect to day 0.  A. Group B(S) 
animals (n = 8).  B. Group B(D) animals (n = 6).  C. Median data for group B(S) and group 
B(D) animals. 
 
 Collectively, there was a consistent weight reduction post-challenge.  Given the age 
and pregnancy status of all animals, significant weight gain over the 10-day period would be 
expected when uninfected.  While the group B(D) animals trended towards greater weight loss, 
the differences in the trends between the two groups were not statistically significant.   
 As with temperature, ranks were assigned to each animal before statistical variance 
was assessed.  Table 3.3 provides a visual representation of the body weight change ranks.  
Despite the lack of statistical difference between the two subgroups, five of the six group B(D) 
animals exhibited the greatest weight loss. 
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Table 3.3: Body weight change ranks for all group B animals based on the summation of the 
body weight changes (i.e. rank sum analysis) from days 1 to 10 of the challenge.  1 = highest 
body weight change summation.  14 = lowest body weight change summation.  Animals were 
assigned ranks (1 – 7) if their sums were in the top half of this ranking order.  Animals were 
assigned ranks (8 – 14) if their sums were in the bottom half of this ranking order. 
Group Animal Label Rank 
B(S) 27 9 
B(S) 30 10 
B(S) 32 12 
B(S) 42 13 
B(S) 43 11 
B(S) 44 7 
B(S) 48 1 
B(S) 49 8 
B(D) 23 6 
B(D) 26 14 
B(D) 31 3 
B(D) 36 4 
B(D) 45 2 
B(D) 50 5 
  
 Similar to the temperature ranking trends, animals with high body weight ranks tended 
to survive the challenge while those with low body weight ranks generally did not survive the 
challenge. 
 
3.4 Induction of and Response to Interferon 
As results from previous studies on induction and response to IFNs during BVDV infection 
have been conflicting, one major goal of this challenge was to characterise IFN trends.  Levels 
for both IFN-α and IFN–γ were assessed on select days pre- and post-challenge to characterise 
IFN induction.  Additionally, expression of genes known to be induced by IFN was examined 
to characterise the cellular IFN response. 
 
 
 
 
 
47 
 
3.4.1 IFN-α 
 
3.4.1.1 IFN-α Induction 
Serum IFN-α levels were examined on days -1, 3, 7, and 10 of the challenge.  Table 3.4 
displays the raw serum IFN-α levels for all animals in the challenge.   
 
Table 3.4: Serum IFN-α levels (pg/mL) on days -1, 3, 7, and 10 of all group A and group B 
animals.  “U” indicates that insufficient serum was available to perform the assay on this day.   
Group Animal  Day 
-1 3 7 10 
A 24 0.00 0.00 0.00 0.00 
A 28 8.91 7.40 8.36 11.10 
A 33 0.00 0.00 0.00 0.00 
A 37 0.00 2.13 0.00 0.00 
A 41 4.88 4.45 3.56 4.01 
A 46 0.00 0.00 0.00 2.73 
A 51 0.00 0.00 0.00 0.00 
B(S) 27 0.00 6.44 5.99 0.00 
B(S) 30 0.00 5.65 5.54 5.99 
B(S) 32 0.00 7.58 3.59 0.00 
B(S) 42 5.20 11.14 9.23 13.08 
B(S) 43 3.47 12.03 6.20 2.88 
B(S) 44 6.71 12.47 17.63 10.55 
B(S) 48 3.71 17.63 11.10 4.88 
B(S) 49 0.00 13.54 4.34 2.88 
B(D) 23 6.56 17.53 10.33 5.54 
B(D) 26 4.85 15.80 8.49 7.12 
B(D) 31 0.00 6.90 5.08 U 
B(D) 36 0.00 10.25 8.07 5.77 
B(D) 45 7.78 71.50 32.08 20.27 
B(D) 50 9.45 47.75 19.92 10.55 
  
 Responding to infection, there was an immediate increase in serum IFN-α levels in the 
group B animals by day 3, the day by which levels peaked in most animals.  These levels 
sharply fell by day 7 and returned to near baseline levels by day 10.  The duration and extent of 
IFN-α elevation is consistent with results gathered from similar BVDV challenge models using 
similar strains (Charleston et al., 2002; Palomares et al., 2013).     
48 
 
 As with the clinical measurements, IFN-α levels on days 3, 7, and 10 of the challenge 
were evaluated as a difference in IFN-α with respect to day -1.  Figures 3.3A, 3.3B, and 3.3C 
show the individual changes within groups A, B(S), and B(D), respectively.  Additionally, 
Figure 3.3D shows the median trends of groups A, B, B(S) and B(D).  Animal 31 was removed 
from median and variance calculations as insufficient serum was collected to make obtain a 
reading from being obtained at that time point. 
  
A      B  
 
C       D  
  
Figure 3.3: Serum IFN-α differences of cattle on days 3, 7, and 10, with respect to day -1.  A. 
Group A animals (n = 7).  B. Group B(S) animals (n = 8).  C. Group B(D) animals (n = 6).  D. 
Median data for groups A, B, B(S), and B(D). 
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 There was a significant difference (p ≤ 0.05) in the serum IFN-α between groups A 
and B based on WRST.  Additionally, both groups B(S) and B(D) exhibited significant 
induction of serum IFN-α relative to group A.  Furthermore, animals in group B(D) tended to 
exhibit higher serum IFN-α relative to group B(S), particularly on day 3.  However, the 
difference was not statistically significant.  Table 3.5 shows the p-values between the various 
groups on days 3, 7, and 10, as well as summed through all three days. 
 
Table 3.5: P-values computed from serum IFN-α level comparisons of various groups on days 
3, 7, and 10, as well as across all three days.  P ≤ 0.05 is considered statistically different. 
Days Group Comparisons 
A vs. B A vs. B(S) A vs. B(D) B(S) vs. B(D) 
3 <0.01 <0.01 <0.01 0.08 
7 <0.01 <0.01 <0.01 0.49 
10 0.12 0.16 0.24 0.91 
All <0.01 <0.01 <0.01 0.34 
 
 As was compiled for the clinical measurements, ranks based on the summation of 
serum IFN-α on days 3, 7, and 10 were displayed to illustrate the qualitative trend, particularly 
between group B(S) and B(D) animals.  Table 3.6 displays these ranks. 
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Table 3.6: IFN-α change ranks for all animals based on the summation of the IFN-γ changes 
(i.e. rank sum analysis) on days 3, 7, and 10 of the challenge.   1 = highest IFN-α sum.  21 = 
lowest IFN-α sum.  Animals were assigned ranks (1 – 7) if their sums were in the top third of 
this ranking order.  Animals were assigned ranks (8 – 14) if their sums were in the middle third 
of this ranking order.  Animals were assigned ranks (15 – 21) if their sums were in the bottom 
third of this ranking order. 
Group Animal Label Rank 
A 24 18 
A 28 17 
A 33 18 
A 37 16 
A 41 21 
A 46 15 
A 51 18 
B(S) 27 11 
B(S) 30 8 
B(S) 32 13 
B(S) 42 7 
B(S) 43 14 
B(S) 44 6 
B(S) 48 4 
B(S) 49 5 
B(D) 23 10 
B(D) 26 9 
B(D) 31 12 
B(D) 36 3 
B(D) 45 1 
B(D) 50 2 
  
 While the three lowest ranking animals perished during the challenge, no clear trend 
was observed regarding whether low or medium ranking IFN-α levels predicted an animal’s 
mortality.  All group A animals were clustered in the highest ranks while all group B animals 
were within the low or medium ranks.  This suggests that, regardless of mortality outcome, 
BVDV stimulated some level of IFN-α synthesis. 
 
3.4.1.2 IFN-α Response: OAS-1, Mx-1, and STAT-1 
While evidence demonstrates that serum IFN-γ is induced in response to BVDV infection, there 
exists potential for disconnect between production of and response to this cytokine as other 
pathogens have been shown to prevent host cells from responding to it (Schweizer et al., 2001).  
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As mentioned, there are multiple well-characterised genes that respond to IFN-α, including 
OAS-1, MX-1 and STAT1 (Sadler et al., 2008).   
 Expression of each of these genes within the group B animals spiked at three days post-
infection and was followed by a gradual decline towards the levels of group A animals.  OAS-
1, Mx-1, and STAT-1 median trends are shown in Figures 3.4A, 3.4B, and 3.4C, respectively.   
 
A      B 
  
C 
   
Figure 3.4: Expression of IFN-α responsive genes. A. Expression of OAS-1.  B. Expression of 
Mx-1.  C. Expression of STAT-1. 
 
 For each of these genes, there was a significant difference in the levels of expression by 
the group B animals relative to the group A animals at days 3 and 7 post-infection, the p-values 
for which are presented in Tables 3.7 – 3.9. 
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Table 3.7: P-values computed from serum OAS-1 level comparisons of various groups on days 
3, 7, and 10, as well as across all three days.  P ≤ 0.05 is considered statistically different. 
Days Group Comparisons 
A vs. B A vs. B(S) A vs. B(D) B(S) vs. B(D) 
3 <0.01 <0.01 <0.01 0.41 
7 <0.01 <0.01 <0.01 0.33 
10 <0.01 <0.01 <0.01 0.63 
All <0.01 <0.01 <0.01 0.41 
  
 
Table 3.8: P-values computed from serum Mx-1 level comparisons of various groups on days 
3, 7, and 10, as well as across all three days.  P ≤ 0.05 is considered statistically different. 
Days Group Comparisons 
A vs. B A vs. B(S) A vs. B(D) B(S) vs. B(D) 
3 <0.01 <0.01 <0.01 0.86 
7 <0.01 <0.01 0.02 0.20 
10 0.12 <0.01 0.52 <0.01 
All <0.01 <0.01 <0.01 0.53 
 
 
Table 3.9: P-values computed from serum STAT-1 level comparisons of various groups on 
days 3, 7, and 10, as well as across all three days.  P ≤ 0.05 is considered statistically different.  
Days Group Comparisons 
A vs. B A vs. B(S) A vs. B(D) B(S) vs. B(D) 
3 <0.01 <0.01 0.18 0.60 
7 <0.01 <0.01 0.13 0.91 
10 0.75 0.36 0.65 0.74 
All 0.02 0.01 0.24 0.82 
 
 OAS-1 exhibited the greatest response to IFN-α stimulation when compared to pre-
challenge levels, with statistical distinction calculated between group A and groups B, B(S), 
B(D).  A similar trend was seen in Mx-1.  This gene exhibited its highest response to IFN-α on 
day 3, but which rapidly fell by day 7.  The temporal kinetics of STAT-1 exhibited the least 
distinction between the various groups.  While there was statistical distinction in comparing 
groups A with B and B(S), this was only significant on days 3 and 7.  Group B(D) animals did 
not statistically separate from the group A animals and neither did the group B subgroups.       
 While the level of statistical distinction between groups A and B was different, there 
was an apparent correlation between IFN-α increase and gene response: early induction and 
subsequent return to baseline levels.  Additionally, there appeared to be a direct relationship 
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between the extent of serum IFN-α increase and the degree of induction of IFN-α-
responsiveness, as seen in Figure 3.5. 
 
A              B  
 
C 
         
Figure 3.5: Correlation between concentrations of serum IFN-α and expression of ISGs.  A. 
OAS-1.  B. Mx-1.  C. STAT-1. 
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3.4.2 IFN-γ 
 
3.4.2.1 IFN-γ Induction 
IFN-γ levels were analyzed in serum samples obtained from the animals on days -1, 3, 7, and 
10 of infection, the values for which are displayed in Table 3.10.   
 
Table 3.10: Serum IFN-γ levels (pg/mL) on days -1, 3, 7, and 10 of all group A and group B 
animals.   
Group Animal  Day 
-1 3 7 10 
A 24 0.00 0.00 1.60 2.04 
A 28 0.00 0.00 0.00 5.67 
A 33 0.00 0.00 0.00 0.00 
A 37 1.29 0.00 1.60 3.13 
A 41 0.00 0.00 0.00 0.00 
A 46 1.60 2.02 2.66 2.48 
A 51 0.00 1.22 1.49 3.29 
B(S) 27 1.18 2.96 5.79 97.23 
B(S) 30 0.54 1.03 9.22 12.57 
B(S) 32 0.83 5.05 13.87 17.40 
B(S) 42 0.00 2.84 7.30 8.37 
B(S) 43 0.00 5.27 6.71 8.37 
  B(S) 44 0.00 1.11 7.67 20.40 
B(S) 48 0.00 3.65 2.96 12.70 
B(S) 49 0.00 15.71 6.12 2.65 
B(D) 23 0.95 8.94 11.49 29.51 
B(D) 26 0.69 4.04 16.40 12.06 
B(D) 31 0.00 1.22 42.66 236.87 
B(D) 36 0.00 2.58 6.04 14.87 
B(D) 45 6.25 10.17 18.35 140.31 
B(D) 50 0.59 16.90 40.80 74.00 
  
 As with the clinical measurements and serum IFN-α levels, IFN-γ levels on days 3, 7, 
and 10 of the challenge were evaluated as a difference in IFN-γ with respect to day -1.  Figures 
3.6A, 3.6B, and 3.6C show the individual changes within groups A, B(S), and B(D), 
respectively.  Additionally, Figure 3.6D shows the median trends of groups A, B, B(S) and 
B(D).   
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A               B  
 
C              D  
  
Figure 3.6: Serum IFN-γ differences of cattle with respect to day -1.  A. Group A animals (n = 
7).  B. Group B(S) animals (n = 8).  C. Group B(D) animals (n = 6).  D. Median Data for groups 
A, B, B(S), B(D).  
 
 The difference in serum IFN-γ levels between groups A and B, as well as between 
group A and the two group B subgroups, was significant (p ≤ 0.05).  Significant distinction was 
also established between group B(S) and group B(D) on day 7 and when all of the days were 
summed, the latter exhibiting substantially higher levels of IFN-γ.  Table 3.11 shows the p-
values between the various groups on days 3, 7, and 10, as well as summed through all three 
days. 
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Table 3.11: P-values computed from serum IFN-γ level comparisons of various groups on days 
3, 7, and 10, as well as across all three days.  P ≤ 0.05 is considered statistically different. 
Days Group Comparisons 
A vs. B A vs. B(S) A vs. B(D) B(S) vs. B(D) 
3 <0.01 <0.01 <0.01 0.57 
7 <0.01 <0.01 <0.01 0.04 
10 <0.01 <0.01 <0.01 0.08 
All <0.01 <0.01 <0.01 0.03 
 
 While distinction between the two subgroups was insignificant on days 3 and 10, there 
was an apparent trend towards increased likelihood of mortality in those animals that exhibited 
high levels of serum IFN-γ.  In addition to the p-values between the various groups, Table 3.12 
shows the ranks assigned to each animal based on IFN-γ serum changes.   
 
Table 3.12: IFN-γ change ranks for all animals based on the summation of the IFN-γ changes 
(i.e. rank sum analysis) on days 3, 7, and 10 of the challenge.   1 = highest IFN-γ sum.  21 = 
lowest IFN-γ sum.  Animals were assigned ranks (1 – 7) if their sums were in the top third of this 
ranking order.  Animals were assigned ranks (8 – 14) if their sums were in the middle third of 
this ranking order.  Animals were assigned ranks (15 – 21) if their sums were in the bottom third 
of this ranking order. 
Group Animal Label Rank 
A 24 18 
A 28 16 
A 33 20 
A 37 19 
A 41 20 
A 46 17 
A 51 15 
B(S) 27 4 
B(S) 30 11 
B(S) 32 6 
B(S) 42 14 
B(S) 43 12 
B(S) 44 8 
B(S) 48 13 
B(S) 49 9 
B(D) 23 5 
B(D) 26 7 
B(D) 31 1 
B(D) 36 10 
B(D) 45 2 
B(D) 50 3 
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 A trend was observed within the data.  Group B(S) animals tended to rank between the 
group A and the group B(D) animals while the group B(S) animals tended to rank low.  All 
group A animals were clustered in the highest ranks while all group B animals were within the 
low or medium ranks.  This suggests that, regardless of mortality outcome, BVDV stimulated 
some level of IFN-γ synthesis. 
 
3.4.2.2 IFN-γ Response: SOCS1 and SOCS3 
As mentioned, many characterised genes – GAS genes – respond to IFN-γ stimulus.  
Additionally, several negative feedback inhibitors – the SOCS genes – are up-regulated as 
cytokine stimulation persists.  SOCS-1 and SOCS-3 are members of this gene family and are 
well-characterised negative feedback inhibitors of IFN-γ stimulus (Larsen and Ropke, 2002).  
Response of these genes to IFN-γ was explored in this challenge.  While evidence demonstrates 
that serum IFN-γ is induced in response to BVDV infection, there exists potential for disconnect 
between production of and response to this cytokine as other pathogens have been shown to 
prevent host cells from responding to it (Hussain et al., 1999; Kierszenbaum et al., 1995; Ray et 
al., 2000).   
 SOCS-1 expression notably increased in group B on day 3 relative to day -1.  This 
increase was short-lived as it drastically fell to near the pre-challenge levels by day 7, as seen in 
Figure 3.7A.  This expression pattern did not mirror the serum IFN-γ trend, which slowly 
increased within the first 10 days (Figure 3.6).  Additionally, there appears to be an indirect 
relationship between serum IFN-γ stimulus and SOCS-1 response, as seen in Figure 3.7B.  
SOCS-1 increased upon initial stimulus, but gradually declined as serum IFN-γ increased.  
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A      B 
 
Figure 3.7: Expression of SOCS-1 in the PBMCs of cattle infected with BVDV.  A. Median 
expression of SOCS-1.  B. P-Values for each compared group. 
 
 SOCS-1 expression was statistically distinct between groups A and B; however, this 
difference was only maintained on days 3 and 7 when group A was compared individually 
compared with the two subgroups.  Additionally, there was no difference between the two 
subgroups temporally or in summation.  The p-values corresponding to these comparisons are 
listed in Table 3.13. 
 
Table 3.13: P-values computed from comparisons of SOCS-1 expression levels between various 
groups on days 3, 7, and 10, as well as across all three days.  P ≤ 0.05 is considered statistically 
different. 
Days Group Comparisons 
A vs. B A vs. B(S) A vs. B(D) B(S) vs. B(D) 
3 <0.01 0.03 0.03 0.45 
7 0.01 0.04 0.03 0.15 
10 0.04 0.06 0.18 0.61 
All <0.01 0.01 <0.01 0.60 
 
 SOCS-3 expression was significantly increased on days 7 and 10 post-challenge in 
group B relative to group A, as shown in Figure 3.8A.  This increased expression mirrored the 
serum IFN-γ levels, in that expression of both gene and cytokine remained elevated until day 10.  
While there was an apparent correlation between serum IFN-γ levels and SOCS-3 expression 
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levels, SOCS-3 induction appeared to plateau by day 7 while serum IFN-γ production continued 
to increase, as seen in Figure 3.8B.    
 
A                                                                   B 
  
Figure 3.8: Expression of SOCS-3 in the PBMCs of cattle infected with BVDV.  A. Median 
expression of SOCS-3.  B. P-Values for each compared group. 
 
 While serum IFN-γ levels were much higher in group B(D), SOCS-3 expression levels 
between this group and group B(S) were not statistically different, as seen by the WRST-
calculated p-values listed in Table 3.14. 
 
Table 3.14: P-values computed from comparisons of SOCS-3 expression levels between various 
groups on days 3, 7, and 10, as well as across all three days.  P ≤ 0.05 is considered statistically 
different. 
Days Group Comparisons 
A vs. B A vs. B(S) A vs. B(D) B(S) vs. B(D) 
3 0.21 0.18 0.50 0.64 
7 <0.01 <0.01 0.01 0.84 
10 0.01 0.03 0.05 0.84 
All <0.01 <0.01 0.05 0.86 
 
3.5 Summary of Clinical and Cytokine Ranks   
Trends were observed in nearly every experiment used to assess ncpBVDV infection.  To 
identify collective trends in the viral presence, clinical, and cytokine data, their ranks were 
compiled together in Table 3.15.  
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Table 3.15: Rank summary for WBC viral presence, nasal fluid viral presence, temperature 
change, body weight change, serum IFN-γ change, and serum IFN-α change.  Animals were 
assigned ranks (1 – 7) if their sums were in the top third of this ranking order.  Animals were 
assigned ranks (8 – 14) if their sums were in the middle third of this ranking order.  Animals 
were assigned ranks (15 – 21) if their sums were in the bottom third of this ranking order. 
Group Animal 
Label 
WBC 
Viral 
Presence 
Sum 
Ranks 
Nasal 
Viral 
Presence 
Sum 
Ranks 
Temp. 
Sum 
Ranks 
Body 
Weight 
Change 
Sum 
Ranks 
IFN-γ 
Sum 
Ranks 
IFN-α 
Sum 
Ranks 
A 24 15 15 N/A N/A 18 18 
A 28 15 15 N/A N/A 16 17 
A 33 15 15 N/A N/A 20 18 
A 37 15 15 N/A N/A 19 16 
A 41 15 15 N/A N/A 20 21 
A 46 15 15 N/A N/A 17 15 
A 51 15 15 N/A N/A 15 18 
B (S) 27 2 2 5 9 4 11 
B (S) 30 8 8 7 10 11 8 
B (S) 32 9 14 9 12 6 13 
B (S) 42 9 10 8 13 14 7 
B (S) 43 5 10 10 11 12 14 
B (S) 44 8 8 3 7 8 6 
B (S) 48 8 2 13 1 13 4 
B (S) 49 8 10 14 8 9 5 
B (D) 23 5 6 11 6 5 10 
B (D) 26 8 6 1 14 7 9 
B (D) 31 3 2 5 3 1 12 
B (D) 36 5 10 12 4 10 3 
B (D) 45 3 1 2 2 2 1 
B (D) 50 1 2 4 5 3 2 
 
 In addition to confirming that the group A animals were appropriate controls in all 
analyses, the results in Table 3.15 suggest that ncpBVDV2-1373 affected animals in groups B(S) 
and B(D) differently.  In four of the six categories, five of the six group B(D) animals are high 
responders and only in one instance do groups B(S) and B(D) have an equivalent 1:1 ratio of 
high and medium responders.  Additionally, the top three responders are group B(D) animals in 
five of the six categories.    
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3.6 Kinome Analysis: JAK-STAT Signalling in PBMCs 
Species-specific peptide arrays have shown to be informative tools for detailing kinome (global, 
cellular kinase) activity in multiple species, including cattle (Jalal et al., 2009).  Recently, 
bovine-specific peptide arrays have highlighted mechanisms by which pathogens guide and alter 
signalling in both monocytes and gut tissues (Arsenault et al., 2012; Arsenault et al., 2013; 
Maattanen et al., 2013).  
 In this investigation, kinome analysis was used on PBMCs obtained from two group A 
animals and two group B animals – one each from groups B(S) and B(D) – on days -1, 3, 7 and 
10.  Individual animals possess unique kinotypes (individual patterns of cellular signalling); as 
with the clinical, cytokine, and gene expression analyses, the signalling profile of each animal 
was assessed against its signalling profile at a pre-challenge time point – day -1 (Trost et al., 
2013).  While the arrays can provide information on global cell signalling patterns, the focus 
within this challenge was on the activity of the JAK-STAT pathway, which mediates signalling 
by both IFN-α and -γ (Shuai et al., 2003).   
 There was no evidence of JAK-STAT signalling in either of the group A animals at any 
of the three time points, as shown in Table 3.16.  Conversely, activation of the JAK-STAT 
pathway was apparent in both of the group B animals at all three of the time points.  
 
Table 3.16: P-values related to kinase activity of the JAK-STAT Pathway (KEGG 568) in 
PBMCs from representatives of both group A and group B. 
Group Animal Day 
3 7 10 
A 28 0.22 0.15 0.52 
A 41 0.13 0.49 0.60 
B(S) 48 0.04 0.02 0.09 
B(D) 50 0.09 0.09 0.06 
 
*Based on levels of differential expression or phosphorylation, InnateDB, a publically available 
pathway analysis tool (Lynn et al., 2008), predicted pathways that are consistent with the 
experimental data.  Pathways were assigned p-values based on the number of proteins present for 
a particular pathway.  For this investigation, fold change cut-offs were set at a p-value of 0.1 for 
confidence of difference between post-challenge and pre-challenge days.  
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 Table 3.16 shows that there was no significant change in JAK-STAT expression of the 
two group A animals relative to day -1 on any of their assessed challenge days.  However, the 
two group B animals showed a significant increase in JAK-STAT phosphorylation across days 3, 
7, and 10, with p-values remaining below 0.10; below 0.05 on days 3 and 7 in animal 48. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
4. DISCUSSION 
 
4.1 Interferon: Barrier to Infection 
Many pathogens, particularly viruses, establish persistent infections to maintain host presence 
and potentiate their lifecycles.  To be successful, these pathogens must counter responses 
initiated by the host’s immune system.  BVDV’s continued prevalence in the environment is 
owed to its ability to manage host cell defenses; even more importantly, establish presence 
within fetal hosts prior to the development of their immune systems.  A major, early barrier to 
establishing host presence is the IFN response.  Most viruses have developed mechanisms that 
downplay immune responses; the first and most important mechanism is often one that stymies 
IFN response.  Viruses may employ a single- or multi-faceted approach; mechanisms of which 
include disabling IFN production, down-regulating IFN receptors, interfering with IFN-mediated 
signalling, or altering the expression and/or activity of IFN-induced effectors (Bonjardin et al., 
2005; Bowie et al., 2008; García-Sastre et al., 2006; Goodbourn et al., 2000; Haller et al., 2006; 
Randall et al., 2008; Versteeg et al., 2010). 
 Substantial research has been performed to identify the tools and mechanisms through 
which BVDV interacts with the host’s immune system.  Numerous studies have been published 
highlighting experiments that have examined host IFN responses using a variety of scenarios that 
have altered the host, the BVDV strain, and the experimental tools that have directly and 
indirectly transcriptionally measured the IFNs – mainly IFN-α – and the levels of IFN-regulated 
gene expression, in order to understand the complete host IFN response to this virus.  Following 
these studies, BVDV’s influence on host IFN responses has been shown to be a complex, multi-
component interaction, which is even more characteristic of non-cytopathic BVDV strains.  A 
previous hypothesis was made that suggested BVDV has three objectives in responding to the 
host immune system and establishing either a transient or a persistent infection: i) prevent IFN 
induction, ii) counter IFN response upon establishment of infection, and iii) avoid interfering 
with IFN action that targets unrelated viruses (Peterhans and Schweizer, 2013).  Such a 
mechanism in establishing self-tolerance requires such complex, multi-component interactions 
with the host in order to avoid viral elimination by IFN processes.   
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 Researchers have generally agreed that the cpBVDV strains stimulate IFN responses but 
there is contention regarding whether ncpBVDV strains also stimulate IFN responses.  There are 
multiple possible reasons for the conflicting conclusions regarding the influence of ncpBVDV on 
host IFN – particularly IFN-α – responses.  These reasons can mainly be summarized in the fact 
that there exists a breadth of genetic and phenotypic variation within BVDV strains that probably 
influences the extent and the mechanism to which the host is immunosuppressed (Palomares et 
al., 2013).  It is important to understand that there is a distinction between the induction of IFN 
and the activity of IFN.  Therefore, to properly understand BVDV’s influence, this discussion 
will separate the information related to the induction and the action of IFN. 
 
4.1.1 Induction of IFN  
Conclusions from past studies suggest that ncpBVDV is capable of infecting host cells when 
type I IFNs have not been induced (Schweizer et al., 2006).  Additionally, several specific 
mechanisms and effectors by which BVDV uses to subvert host type I IFN responses have been 
defined, particularly the degradation of IRF-3 via Npro activation, which limits transcriptional 
activation of the IFN-β gene (Seago, et al., 2007).  Furthermore, Erns degrades viral RNA to limit 
host responses to BVDV (Rumenapf et al., 1993; Schneider et al., 1993).  These two effectors 
are pivotal in order for BVDV to successfully infect the host (Meyers et al., 2007). 
 This thesis has provided evidence for the induction of both IFN-α and IFN-γ in response 
to ncpBVDV infection.  In particular, there was a significant, transient increase in serum levels 
of both cytokines (p < 0.05) in response to BVDV infection.  IFN responses to viral infection are 
often temporary and self-controlling in order to avoid pathological consequences that include 
disruption of both the normal immune response and blood cell development as a consequence of 
extended IFN stimulation (Abbas et al., 2005; Gånheim et al. 2003; Lin et al., 1998; Tråvén et 
al., 1991).  Within group B, the highest producers of IFN-α tended to be the group B(D) animals; 
although, the group B(D) to B(S) comparison was not statistically significant.  However, when 
comparing group B to group A, levels of serum IFN-γ were statistically different (p < 0.01).  
Additionally, group B(D) exhibited higher levels of serum IFN-γ (p < 0.05), which suggested 
that serum IFN-γ reflects the severity of ncpBVDV2-1373 infection.  
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4.1.2 Action of IFN 
Following establishment of its presence within the host, evidence suggests that BVDV is 
unaffected by IFN-α if it’s synthesized due to host cell infection by another pathogen.  Past 
studies have demonstrated that cells treated with IFN-α prior to BVDV challenge are able to 
utilize this host defense to respond to BVDV while the same treatment, when provided post-
infection, is ineffective (Peek et al., 2004; Schweizer et al., 2006).  Notably, the ability of BVDV 
to avoid being cleared from the host during IFN-α response appears specific to this virus as 
BVDV-infected cells treated with IFN-α were guarded from infection by different viruses 
(Schweizer et al., 2006).  Within in vitro analyses, BVDV is able to counter the action of IFN-α 
even after extended passages in the presence of elevated IFN-α levels (Schweizer et al., 2006).  
Consistent with the inability of BVDV-infected cells to induce IFN-mediated responses that clear 
the pathogen in vitro, treatment of BVDV-infected cattle with recombinant IFN-α failed to 
reduce viremia (Peek et al., 2004).  Researchers have suggested that BVDV may impact the 
immune environment of the infected cells via regulating of NF-κB through the use of protein 
kinase R and/or IRFs (Taniguchi et al., 2002). 
 This study has provided evidence, which has shown that PBMCs from ncpBVDV 
infected animals remain responsive to both IFN-α and -γ.  Notably, while immunocytochemical 
experiments demonstrated that BVDV was present within the WBCs, PBMCs represent a 
mixture of blood cell types with respect to their infection status.  Therefore, both infected and 
uninfected cells might have differential capabilities in responding to IFN in that the infected cells 
do not respond to IFN.  However, the ability of IFN to guide the clearance of unrelated viruses 
from BVDV-infected cells would also suggest that these cells still have functional IFN.  
Acknowledging the IFN responsiveness of the PBMCs questions whether BVDV is able to 
immunocompromise the host and suggests a complete downplay of IFN responsiveness.   There 
was clear induction of gene expression of those genes known to be controlled by both IFN-α and 
–γ.  Additionally, both the temporal characteristics and extents of induction of these genes 
trended similarly with the levels of the cytokines that regulated them. 
PBMC responsiveness to IFN within BVDV-infected animals was further confirmed via 
kinome analysis.  As a pivotal component to their infection, various pathogens, particularly those 
establishing chronic infections, manipulate host cellular signalling responses (Bowie et al., 2008; 
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Brodsky et al., 2009; Kim et al., 2008; Reddick et al., 2014).  Therefore, studies examining host-
pathogen interactions at the level of kinase-mediated signal transduction enable the 
understanding of cellular mechanisms connected with potent pathogen elimination; additionally, 
mechanisms used by the pathogen to avoid host defense.  PBMC kinome analysis of 
ncpBVDV2-1373-infected cattle showed consistent and persistent activation of the JAK-STAT 
signalling pathway relative to the signalling activity of PBMCs before challenge was infected.  
Conversely, kinome analysis elucidated no evidence of JAK-STAT activation in the PBMCs of 
the group A animals.  The combination of JAK-STAT activation with increased IFN-regulated 
gene expression is consistent with results of prior in vitro experiments (Baigent et al., 2004; 
Schweiser et al., 2006). 
 
4.2 Clinical Outcomes 
Characterising temperature and body weight changes is relevant as veterinarians and clinicians 
use these measures to track the health of an animal and the progression of illness.  The temporal 
pattern of temperature change observed in this challenge follows a pattern that was previously 
observed under similar BVDV challenges (Ellis et al., 1998; Liang et al., 2006; Snider et al. 
2014; van Drunen Littel-van den Hurk et al., 2013).  Apart from clinically confirming the 
challenged animals were sick, the temperature change pattern added further evidence to classify 
the initiated BVDV infection as acute.  Past evidence has shown that, in addition to leukopenia, 
increased body temperature is characteristic of acute BVDV infection (Liebler-Tenorio et al., 
2003b), a result that contrasts with infection by low virulence strains (Bolin and Ridpath, 1992).  
 
4.3 Predictive Markers for Mortality 
While the mortality rate of the challenged cattle was unexpected, it enabled the testing of the 
clinical scores, the cytokines, and the regulated genes as predictive markers for mortality.  While 
expectations would suggest that greater changes in clinical responses and higher spikes in 
immune system cytokines tend to favour increased likelihood of mortality; in this study, semi-
quantitative and statistical assessments were performed to examine the usefulness of each marker 
as a mortality predictor.  The desire to assess these markers was the reason for the subdivision of 
the group B animals.  It was through subgroup B comparisons that these markers were examined.   
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 Clinical signs are the most practical method to assess the course a disease may take as 
veterinarians are much more likely to examine changes in temperature and body weight over 
serum cytokine levels.  These clinical changes are reliably used to assess an illness and were 
practical measures to assess BVDV infection in this challenge.  During the course of the 
challenge, temperatures and body weights deviated; as expected, the group B(D) animals 
exhibited sharper variations in temperature change and body weight loss.  However, a statistical 
comparison between both groups suggested the difference in clinical scores between both groups 
was insignificant.  This was easy to see with temperature scores in Tables 3.2 and 3.15: four of 
the group B(D) animals ranked within the top five temperature responders, but the remaining two 
animals ranked very low.  While five of the six group B(D) animals ranked among the top six 
animals in terms of body weight decrease, one animal within group B(S) exhibited the greatest 
weight drop.  Additionally, the sixth animal in group B(D) exhibited the smallest body weight 
decrease among the fourteen.  While decreased body weight change tended to favour increased 
likelihood of mortality, the outliers likely prevented statistical significance from being attributed.   
 The IFNs exhibited differential levels of reliability in predicting mortality.  Firstly, while 
the highest IFN-α producers were among group B(D), the high and medium responders were 
equally divided between groups B(S) and B(D).  Even before calculating a p-value to assess the 
difference between the groups, Tables 3.6 and 3.15 illustrated a lack of distinction between the 
two subgroups and strongly suggest IFN-α is an unreliable predictive marker.  Conversely, IFN-γ 
was a more convincing predictive marker.  Five of the six group B(D) animals ranked as high 
responders and the top two responders were both group B(D) animals.  Additionally, the p-value 
calculated from cytokine levels summed from data on days 3, 7, and 10 showed the distinction 
between the two groups was significant.  As such, IFN-γ arose as the only reliable marker for 
mortality within this challenge. 
 One difficulty in accepting the mortality results as valid is the sample size that was 
assessed.  A fourteen-animal sample size is a small sample size under which to properly assess 
markers for mortality.  This is particularly evidenced within the body weight data, which 
exhibited two outliers for each subgroup at the opposite ends of the animal ranks.  It is well 
known that outliers in smaller sample sizes have greater abilities to skew trends within data.  For 
example, body weight change is a well-known method of assessing severity of pathogen 
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infection; as such, it would be expected to be a more reliable predictive marker.  The outliers in 
the ranks likely prevented statistical significance from being applied.  As such, in order to 
properly assess predictive mortality markers, a larger sample size should be used.  The results 
from this challenge suggest that IFN-γ warrants further investigation as a predictive marker.   
 
4.4 Application of Peptide Arrays to Host-BVDV Interaction 
While the only results presented in this study were related to the JAK-STAT pathway, the 
peptide arrays were utilized to examine global pathway changes between groups A and B relative 
to pre-challenge pathway profiles.  Kinome analysis represents a novel tool through which 
further assessment of BVDV could be explored.  The peptide array technology used to analyse 
kinase-mediated signal transduction is a novel and relatively new tool that has already been used 
to examine signalling alterations caused by antigen stimulation and pathogen infection 
(Arsenault et al., 2009; Arsenault et al., 2012; Arsenault et al., 2013).   
 As these arrays are assembled by synthetically creating and attaching multiple unique 15-
mer peptides that represent phosphorylation sites of well-known protein kinases, data obtained 
from the arrays requires validation by additional experimental means, i.e. ELISAs, Western 
blots, or qRT-PCRs.  Therefore, while the arrays provide a substantial amount of information, 
the information they elucidate must be confirmed.  Interestingly, the peptide array data in this 
thesis is presented in reverse order in that JAK-STAT signalling is used to “validate” the 
cytokine and gene expression data.  While these peptide arrays cannot validate the information 
from those experiments, they do provide another independent assessment of immune response.  
JAK-STAT signalling is often indicative of immune response as IFNs use this pathway to 
regulate various genes; as such, its activation provides additional evidence for the induction of 
IFN in this challenge.  
 InnateDB produces information on differential phosphorylation within both pathways and 
individual kinases (Lynn et al., 2008).  These arrays have been used to examine the 
phosphorylation states of various JAKs and STATs, as well as well-characterised kinases within 
TLR pathways.  As such, a more detailed examination of the phosphorylation states of select 
kinases could identify kinases as targets for BVDV infection; furthermore, as biomarkers on 
which to predict infection status or likelihood of mortality, or even against which to develop 
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novel therapeutics.  Additionally, as these arrays are convenient tools to examine global 
signalling changes, they are very useful in guiding researchers to notable signalling events that 
could be further assessed.  These events could include networks associated with growth, 
apoptosis, and the cell cycle.  Overall, these arrays have been shown to detect changes in host-
BVDV interaction (host signalling patterns caused by BVDV-infection) and represent novel 
tools on which to expand research into biomarker identification and characterisation of strain-
specific BVDV infection.   
 
4.5 Future Work  
As the original goal of this study was to examine clinical and biochemical changes in animals 
persistently infected by BVDV, a future study could reattempt establishment of a persistent 
infection.  This could be done by lowering the administered viral dose or by using a strain that is 
less virulent than the 1373 strain.  The NY-1 strain is a potential substitute.  The analyses 
conducted in this challenge could also be used in that future challenge.  One additional 
component to that challenge could be the separation of PBMCs into their individual cell 
populations, or else isolating one of those populations to conduct clinical and biochemical tests.  
 This study has answered several questions; notably, addressed the contention regarding 
the ability of ncpBVDV to induce an IFN response.  While this contention was mainly regarding 
the IFN-α, this study provided solid evidence that both IFN-α and -γ are induced by 1373.  As 
mentioned, past studies have demonstrated that cpBVDV strains induce IFN response.  Because 
1373 exhibits both non-cytopathic and cytopathic characteristics, analysis of IFN induction 
should further be assessed by a less virulent, non-cytopathic strain; as such, NY-1 is a good 
candidate in both establishing a persistent infection and in further examining IFN induction.  
Results from that future challenge would further cement BVDV’s status as an IFN-inducer.  
 Apart from demonstrating its induction, this study also identified IFN-γ as a potential 
predictive marker for mortality.  As the animal sample size was relatively small, its status as a 
predictive marker should be further tested on a larger sample size.  This could be done as a 
secondary objective in a future animal trial; albeit, in a challenge that would likely need to again 
utilize 1373 or another virulent BVDV strain.  A challenge consisting of two groups – one 
70 
 
infected with NY-1 and the other infected with 1373 – would be useful in providing data on IFN 
induction and mortality assessment. 
 Finally, future experiments could expand on the use of peptide array technology to 
analyse animal kinotypes.  It is clear from this thesis, in addition to previous studies, that kinome 
analysis was able to elucidate host cell signalling information caused by host-pathogen 
interaction.  This technology could be further explored in future studies, particularly as a 
component of future BVDV challenges.  Such uses of the arrays could include examining the 
changes of specific kinases between challenged animals; identifying potential biomarkers which 
could identify disease status, predict potential outcome, or act as targets against which new 
therapeutics could be developed. 
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5. CONCLUSIONS 
In conclusion, this study identified ncpBVDV2-1373 as an inducer of both IFN-α and IFN-γ 
within bovine sera.  These results help dispel past controversy regarding the status of non-
cytopathic BVDV as an IFN-inducer.  Additionally, this study provided solid evidence that the 
animals successfully responded to these cytokines.  Genes known to be regulated by IFN-α – 
OAS-1, Mx-1, and STAT-1 – and IFN-γ – SOCS-1 and SOCS-3 – were shown to express in 
temporal patterns similar to their regulatory cytokines.  The results of this challenge also 
suggested that IFN-γ shows promise as a potential predictor of mortality to BVDV infection as 
the cytokine’s levels between groups B(S) and B(D) were statistically distinct on day 7 post-
infection, as well as across the three post-infection days combined.  Finally, peptide arrays 
assessing kinome profiles predicted increased phosphorylation within the JAK-STAT signalling 
network of PBMCs that were isolated from the group B cattle, a prediction which adds evidence 
that ISGs and GAS genes were signalled by IFNs.  As such, these arrays show promise as novel 
tools through which to predict and further examine the specific mechanisms of host-BVDV 
interaction at the level of kinase-mediated phosphorylation.   
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